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1 Introduction 
Diuretics 
Diuretics are agents that stimulate the production of urine. In this defini-
tion also water is an example of a diuretic. It provokes intense diuresis if 
taken in sufficiently large dosages. Popular drinks such as coffee and beer 
have well balanced diuretic properties, caused by caffeine and ethanol. ,,' 
Many other substances in our food and drinks have mild diuretic effects. 
For therapeutic goals however, pharmacological agents were synthesized 
with a much stronger diuretic action, and this thesis deals with the role 
of these diuretic drugs in medical practice today. 
In 1920, Saxl and Heilig' reported the diuretic effect of the antisyphilitic 
drug mercaptomerin sodium. This was the first breakthrough in diuretic 
therapy and until the 1950'S these organomercurial diuretics were used in 
the treatment of water and salt retention syndromes. Their toxic side 
effects, parenteral administration and limited efficacy precluded wide-
spread use. 
In 1957, chlorothiazide was reported to increase the excretion of Na+, cr 
and H,O.4 This was the second breakthrough in diuretic therapy, and 
chlorothiazide together with many of its derivates, soon categorized as 
thiazides, became widely used drugs. Thiazides are effective and relatively 
safe drugs in the treatment of many clinical disorders characterized by 
water and salt retention. The treatment of congestive heart failure im-
proved tremendously by the introduction of this group of diuretics. 
Thiazides also have blood pressure lowering effects and until today are 
drugs of first choice in the treatment of hypertension. 
The development of furosemide and its congener diuretics in 1963 was the 
third breakthrough in the field of diuretic therapy.,·6 Their diuretic effect 
is considerably stronger than that of thiazides. Because of the site of 
action they are known as loop diuretics or, referring to their diuretic 
potency, high-ceiling or high-efficacy diuretics. Thiazides can elicit 5% 
of the ultrafiltrated Na+ in the urine, while loop diuretics can elicit up to 
20%. Furosemide and other loop diuretics are indispensable drugs in the 
management of heart failure. 
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In the same period furosemide was introduced, potassium sparing diuret-
ics were synthesized; first the competitive antagonist of aldosterone, spi-
ronolactone, and later triamterene and amiloride, both directly acting 
upon the tubular epithelium. All thiazide- and furosemide-like diuretics 
cause loss of K+, and thus potassium sparing diuretics constitute a wel-
come addition to the diuretic armamentarium, although their intrinsic 
diuretic effect is weak.7 •• 
New (classes of) diuretics will certainly become available. Examples of 
diuretics that are in the experimental phase are atrial natriuretic peptides, 
antivasopressins (=anti-ADH), and so called 'acquaretics', that regulate 
the water transport through cellular water channels.'·w 
Indications for diuretic treatment 
Hypertension and heart failure are the two main indications for diuretic 
therapy, each responsible for 30-40% of all diuretic prescriptions: The 
remainder is prescribed for a variety of conditions accompanied by water 
and salt retention, such as hypostatic ankle oedema, liver cirrhosis and 
nephrotic syndrome. 
Heart failure is characterized by insufficient blood circulation. One of the 
compensatory mechanisms is retention of salt and water by the kidney. 
Consequently, blood volume and preload (i.e. volume supply) of the 
heart are increased, which to a certain extent improves blood circulation. 
In many patients, however, fluid retention becomes too abundant and 
contra productive, and worsens the symptoms of heart failure and may 
eventually lead to pulmonary oedema with severe dyspnoea. Diuretic 
therapy is very effective in these cases. H Several classes of drugs are avail-
able to treat heart failure, but diuretic therapy has been and still is a cor-
nerstone in heart failure therapy since more than three decades. ".'3 
Diuretics lower blood pressure; thiazides more effectively than loop diu-
retics. The mechanism is not completely elucidated, but decrease of 
intravascular volume and presumably vasodilatation playa role. Large 
placebo-controlled trials have demonstrated the efficacy of diuretic treat-
ment in hypertension.'4." It is beyond doubt that diuretic therapy de-
creases the incidence of strokes. In addition, the incidence of ischemic 
cardiac disease is reduced or at least postponed. Side effects are generally 
acceptable, albeit an increased risk of sudden cardiac death caused by 
• This thesis, chapter 7 
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diuretic-induced electrolyte depletion has been suggested to negatively 
influence the beneficial effects of diuretics on survival.'6", 
Adverse effects of diuretics 
Several overviews of the potential adverse effects of diuretics are avail-
able. For extensive literature references we refer to McInness' chapter in 
the authoritative textbook: Meyler's side ellects of drugs.·8 An illustrative 
but incomplete summary is given in Table 1.I Reported side effects range 
from alopecia to sudden death. 
Not all side effects are harmful. A thiazide-induced reduction in renal 
clearance of calcium may prevent renal stone formation in hypercalciurla 
and the related increase in plasma calcium levels may prevent or post-
pone osteoporosis. Two studies demonstrated a clinically relevant de-
crease in the risk of hip fractures of approximately 30% in recipients of 
thiazides,lg,2o 
Besides adverse effects, a large number of possible interactions with other 
drugs has been reported. The majority of patients prescribed diuretic ther-
apyis relatively old and the clinical relevance ofpharmacologicallnterac-
tions of diuretics is augmented by the high prevalence of polypharmacy 
in the elderly. 
Overuse of diuretics in the elderly? 
Approximately 20% of all men and women of 65 years or older, and 50% 
of those over 80 years of age, use diuretic medication every day, for many 
years in a row." This illustrates that these drugs rank high in the list of 
most frequently prescribed drugs." 
It is unclear whether the long-term use of these medications on such a 
large scale is justified. Although heart fallure and hypertension are com- _' 
mon in the elderly, the high prevalence of these disorders cannot fully 
explain these high prescription rates. Several publications have ques-
tioned the rationale for this widespread use. '3 Polypharmacy in the el-
derly is a recognized medical problem and all prescribing physicians and 
patients would agree that unnecessary medication should be avoided or 
withdrawn. An important factor that might cause overuse of diuretics is 
the unwillingness of doctors and patients to stop medications that are 
perceived as being useful. Once started, diuretic therapy will not easily be 
discontinued. 
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Table 1.1 
Adverse effects of diuretics (adapted from Mcinnes 1992) 
Hypovolemia 
Orthostatic hypotension ~> falls and fractures 
Mesenteric infarction 
Stroke 
Confusion, drowsiness 
Hyponatremia 
Fatigue 
Encephalopathy, convulsions 
Hypo/Hyperkalemia 
Cardiac arrhythmia, sudden death 
Hypomagnesemia 
Hypo/hypercalciuria 
Renal stones 
Hypo/hypercalcemia 
Increase of blood glucose concentration 
Reduced insulin sensitivity 
Hyperuricemia 
Gout 
Increase in serum cholesterol 
Sexual impotence, decrease in libido 
Dizziness, tinnitus, deafness 
Visual disturbances 
Thrombocytopenia, neutropenia, eosinophilia 
Haemolytic anaemia 
Skin rashes, urticariae, photosensitivity, chloasma 
lupus erythematodes 
Alopecia 
Drug fever 
Allergic vasculitis 
Allergic interstitial pneumonitis 
Anaphylactic shock 
Cholestatic jaundice 
Precipitation of hepatic coma in patients with hepatic failure 
Stevens-Johnson syndrome 
Biliary colic 
Pancreatitis 
Nausea, vomiting, diarrhoea 
Inappropriate antidiuretic hormone secretion syndrome 
Acute urinary retention 
Urine incontinence 
Nephrotoxicity, interstitial nephritis 
Gynaecomastia 
Folic acid deficiency 
1 Illtroductioll IS 
The main study included in this thesis aims to assess what proportion of 
elderly patients on long-term diuretic therapy can be successfully with-
drawn. Two earlier randomized controlled studies among hospitalized 
patients suggested that a major part of the elderly could be withdrawn 
from diuretic therapy."'" Several uncontrolled studies on cessation of 
diuretics produced variable results, ,6.'7.,8.'9 while one uncontrolled study 
in the general practice setting showed a considerable risk of cardiac com-
plications.3o Finally, a randomized trial in general practice of withdraw-
ing diuretics in a highly selected group of patients with non-cardiacankle 
oedema (which is a dubious indication for diuretic therapy), demon-
strated that 78% could stop diuretic therapy.3' 
Structure of this thesis 
The central part of this thesis is formed by the description of the results 
of two studies on withdrawal of diuretics. The immediate cause to exe-
cute these studies was the impression that prescriptions for diuretics in 
elderly patients seemed to be repeated endlessly. To assess whether such 
long-term use of diuretics was justified, the following research questions 
were addressed: 
1. What proportion of elderly patients on long-term diuretic therapy 
may be successfully withdrawn from this therapy? 
2. What are the effects of withdrawal of diuretic therapy on blood pres-
sure, heart failure symptoms, and blood parameters? 
3. What are predictors for successful withdrawal? 
The current role of diuretics in the therapy of heart failure and hyperten-
sion was assessed by reviewing the available national clinical guidelines 
on heart failure and hypertension (Chapters 2 alld 3). 
Methodological particularities of drug withdrawal studies are discussed 
in Chapter 4. A study was performed to assess the accuracy of the auto-
matic blood pressure measuring device that was used in the diuretic with-
drawal trial (C//apter 5). 
In an uncontrolled pilot study among IS patients receiving diuretic ther-
apy in one general practice the logistics and the measurement instru-
ments of the study were tested (C//apter 6). Subsequently a randomized, 
placebo-controlled, double-blind, trial assessing the effects of withdrawal 
from diuretics was performed in 202 patients from 8 general practices in 
the vicinity of Schoonhoven (Chapter 7). 
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The general discussion (Cllapter 8) elaborates on the potential con-
sequences for medical practice of the studies included in the thesis, and 
recommendations for withdrawing diuretics in general practice are given. 
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Introduction 
Heart failure is a chronic disease caused by a diminished cardiac pump 
function. Breathlessness and fatigue, occurring at subnormal levels of 
exercise or even at rest are the most prominent symptoms. Insufficient 
blood circulation, together with dysfunctioning of compensatory mecha-
nisms, leading to volume overload and increased sympathetic activity, 
generate a scala of symptoms and physical signs that form the variable 
clinical picture of chronic heart failure. 
The number of patients with heart failure is increasing, mainly because 
of ageing of the population and increased survival after myocardial in-
farction.'" The prevalence of the disease increases with age: 80% of all 
heart failure patients are older than 75 years and ten percent of those 
above 80 years of age have heart failure. In the Netherlands most of these 
elderly patients are diagnosed and treated by general practitioners.3 
Since the introduction of chlorothiazide in 1957 and of furosemide in 
1963, diuretics have been cornerstones in the treatment of heart failure. 
Early experimental studies demonstrated their efficacy.4",6" Other drugs 
widely used in the treatment of heart failure are digoxin, angiotensin-
converting-enzyme (ACE) -inhibitors and nitrates. 
ACE-inhibitors were introduced in the Netherlands around 1983. While 
diuretics diminish excessive water and salt retention, ACE-inhibitors 
induce vasodilation and block neurohumoral (over)stimulation.8 Their 
efficacy if added to existing therapy, in patients with moderate or severe 
heart failure, was demonstrated in several randomized trials,9,ro,u,I2 The 
increasing evidence of the efficacy of ACE-inhibitors in the treatment of 
heart failure resulted in a progressively important role of these drugs. 
Effectiveness of ACE-inhibitors in symptomatic heart failure, however, 
was only demonstrated, if added to diuretic treatment. Before trials com-
paring monotherapy of diuretics with monotherapy of ACE-inhibitors 
become available, conclusions that ACE-inhibitors are superior to diuret-
ics renlain preInature. 
The classification of systolic versus diastolic left ventricular dysfunction 
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has recently been recognized to be important for understanding the 
underiyingmechanisms, and for guiding therapy of heart failure. Systolic 
ventricular dysfunction is characterized by decreased contraction capac-
ity of the left ventricle, and diastolic ventricular dysfunction is character-
ized by inadequate end-diastolic filling of the left ventricle, generally 
caused by decreased relaxation capability of the left ventricular muscular 
wall. These subtypes are functional categories (diagnosed with functional 
tests such as echocardiography) and should not be confused with the 
clinical categories of forward and backward (congestive) heart failure. 
Systolic and diastolic dysfunction both may produce clinical symptoms 
of forward and backward failure. It has been suggested that the distinc-
tion between systolic and diastolic dysfunction in heart faibre patients 
has important therapeutic consequences. Because most patients suffer of 
combined systolic and diastolic dysfunction with a predominating sys-
tolic component, the label 'chronic heart failure' in this chapter refers to 
this group. A minority of patients predominantly suffer from diastolic 
dysfunction; this group is addressed in separate paragraphs on 'heart fail-
ure caused by diastolic dysfunction'. 
It is not easy to keep up with all new scientific evidence pertaining to the 
treatment of heart failure. Many original studies, meta-analyses, reviews 
and editorial comments on the issue are being published yearly. The di-
versity of the results and, notably, of the conclusions and recommenda-
tions in these publications may pose problems for practising physicians. 
Under these circumstances national clinical guidelines may offer a possi-
ble solution. The general aim of such guidelines is improvement of qual-
ity of medicai care by providing physicians with solid and unambiguous 
recommendations about, notably, diagnostic and therapeutic manage-
ment of specific problems. National clinical guidelines may be considered 
as evidence-based, pragmatical reports with potentially a large impact on 
medical practice in the country of origin. 
In view of the recent developments in the therapy of heart failure and by 
studying six available national clinical guidelines on management of 
heart failure we assessed the current role of diuretics in the treatment of 
heart failure. The three following questions were addressed in detail: (I) 
Are diuretics, ACE-inhibitors, or the combination of the two drugs cur-
rently recommended as treatment of first choice in chronic heart failure? 
(2) What types of diuretics and what dose titration schedules are recom-
mended for the treatment of mild to moderate heart failure, and for se-
vere heart failure with persistent edema? and (3) Do the recommenda-
tions regarding diuretic treatment differ in patients with diastolic and 
systolic ventricular dysfunction? 
Table 2.1 
Characteristics of the reviewed national guidelines on the treatment of heart failure 
Guideline Year of publication Initiative Medica! specialty of authors (# of persons in the 
working party) 
Sweden 1993 Medica! Products Agency of the Cardiology (18), General practice (2), Internal 
Swedish administration medicine (2), Clinical pharmacology (1) 
Canada 1994 Canadian Cardiovascular Society Cardiology (27), Cardiac-surgery (3) 
Netherlands-eSO 1994 National Organization of Medical Cardiology (6), General practice (3), Pharmacy 
Quality Insurance (CBO) (3), Geriatrics (2), Patients (1), Epidemiology (1), 
Internal medicine (1), Radiology (1) 
US-AHCPR 1994 US Department of Health and Human Cardiology (5), Cardiac surgery (2), Geriat-
Services. Agency for Health Care Pol~ riCS/lnternal medicine (2), Nursing (2), Patients 
icy and Research (2), General practice (1), Pharmacy (1), 
Pulmonology (1) 
Netherlands-GP 1995 Dutch College of General Practitio- General practice (7) 
neTS (NHG) 
US·ACC/AHA 1995 American College of Cardiology and Cardiology (23) 
the American Heart Association 
~---
------
Target group 
All physicians 
All physicians 
All physicians 
All physicians 
General 
practitioners 
All physicians 
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Methods 
The six available national clinical guidelines were traced by searching the 
Medline database 1991 to 1996 on CD-ROM, exploring references from 
relevant publications and by asking experts in the field. Only guidelines 
published in English, German, French or Dutch were sought. Although 
a European guideline on diagnostic procedures in heart fail ure patients 
was published, a similar guideline on therapy was not available at the 
time of preparation of this review. 
The guidelines were scrutinized with respect to our specific questions 
about the current role of diuretic treatment in chronic heart failure. 
Results 
Characteristics of the guidelines (fable 2.1) 
At the time of preparation of this manuscript six recent national guide-
lines on heart failure were available: two from the USA, '3,'4 two from the 
Netherlands,'s,'6 one from Canada," and one from Sweden." The first US 
guideline is one of a series of national clinical guidelines of the Agency 
for Health Care Policy and Research (AHCPR) of the US Department of 
Health and Human Services; the second is a joint publication of the 
American College of Cardiology and the American Heart Association 
(ACC/AHA), The first Dutch guideline was developed by the National 
Organization of Medical Quality Insurance (CBO), a fully government 
sponsored organization. The second Dutch guideline was produced by 
the Dutch College of General Practitioners (GP). The Canadian guideline 
is the product of the Canadian Cardiovascular Society. The Swedish Med-
ical Products Agency, which produced the Swedish guideline, is an orga-
nization of quality insurance, comparable to the Dutch Medical Quality 
Insurance Organization. 
The year of publication varied from 1993 to 1995. Governmental or medi-
cal professional organizations took the initiative and formed working 
parties of experts with the task to write a concept of the guideline. The 
exact way of formation of these working parties varied, as did the proce-
dures for adjustment of the concepts, final approval and publication. A 
detailed description of the procedures of the development of the guide-
lines is summarized in the introductory sections of the guidelines,'3 in 
separate publications, '9 or may be obtained from the organizers'3,"'" Most 
working parties were recruited from a variety of medical specialists, but 
two working grou ps were restricted to card iologi sts or cardiac surgeons'3," 
and one included only general practitioners,6 (Table 2.1). All but the 
Table 2.2 
Combination therapy versus monotherapy with diuretics and ACE-inhibitors in the treatment of chronic heart failure 
Guideline Diuretics combined Diuretics without ACE-inhibitor ACE-inhibitor without diuretics 
with ACE-inhibitors 
Sweden Standard Yes, mild HF with fluid retention, and EF >40% No, generally not 
Canada Standard Contradictory: 'Yes, but rarely' and 'ACE-inhibitors Yes, patients without volume 
in all symptomatic patients' overload 
Netherlands-eBO Standard Yes, only very old patients, for whom slight im- Yes, patients without volume 
provement of mortality counts less than morbidity overload 
US-AHCPR Standard No Yes, patients without volume 
overload 
Netherlands-GP Only if symptoms on ~ 1 Yes, if asymptomatic on ~ 1 DOD diuretics No 
DOD diuretics 
US-ACC/AHA Standard Only in patients with predominantly diastolic HF Yes, patients without volume 
overload 
AHCPR = Agency for Health Care Policy and Research from the US Department of Health and Human Services, CBO = National Organization of Medical 
Quality Assurance, GP= General practitioners, NHG = Dutch Scientific Society of General Practitioners, ACC = American College of Cardiology, AHA = 
American HeartAssociation, EF = ejection fraction, DOD = defined daily dose, HF = heart failure 
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Dutch GP guideline pertain to patients in both the hospital and the pri-
mary care setting. This latter guideline was written exclusively by general 
practitioners, but cardiologists and internists reviewed the manuscript 
and were consulted during a discussion meeting. It provides recommen-
dations for patients in general practice only. 
Diuretics monotherapy versus combination therapy with diuretics 
and ACE-inhibitors in the treatment of chronic heart failure (Table 
2.2) 
All but one guideline recommend the combination of diuretics and ACE-
inhibitors as standard treatment for chronic heart failure. The Dutch GP 
guideline recommends diuretic monotherapyfor patients with mild heart 
failure. Addition of ACE-inhibitors is recommended only when diuretic 
dosages larger than I DOD (defined daily dose) are needed to keep pa-
tients symptom-free. In certain subgroups of patients, the Swedish, the 
Canadian, the Dutch CBO and the US-ACC/AHA guidelines also leave 
room for monotherapy with diuretics. For example, the Swedish guide-
line advises monotherapy with diuretics in patients with fluid retention 
and normal ejection fractions (>40%), and the Dutch CBO advises symp-
tomatic treatment (e.g. diuretic monotherapy) in very old patients. 
ACE-inhibitors as monotherapy in patien ts without symptoms of volume 
overload are advised by the Canadian, the US-AHCPR, the Dutch CBO, 
and the US-ACC/AHA guidelines. According to these guidelines, one 
should start with ACE-inhibitor therapy, in incident cases of heart failure 
without volume overload, and add diuretics only when volume overload 
develops. Most new heart failure patients, however, present themselves 
with symptoms of volume overload'o and in these cases the generally 
recommended treatment sequence is to start with diuretics and add ACE-
inhibitors later, with special attention to avoid underhydration, since 
this may cause severe hypotenSion when the first dose of ACE-inhibitors 
is administered. Up-titra tion of ACE-inhibitors to the average dosage used 
in the clinical trials is recommended in all clinical guidelines. Duringthis 
up-titration of ACE-inhibitors, diuretics should be titrated down to the 
lowest possible dose. Most guidelines warn against the prescription of too 
high dosages of diuretics, because this may impair adequate up-titration 
of ACE-inhibitors to target dose levels. 
Types and dosages of diuretic treatment in mild to moderate heart 
failure (Table 2.3) 
All guidelines recommend thiazide diuretics in patients with mild vol-
ume overload and loop diuretics in more severe cases. In four of the 
guidelines thiazides are also preferred as maintenance therapy in clini-
cally stable heart failure patients, while in the Canadian and the US-
Table 2.3 
Choice of diuretic treatment in mild to moderate heart failure 
Guideline Start in mild HF of recent onset Start in moderate to severe 
HF of recent onset' 
Sweden Thiazides@ Furosemide 20-40 mg or 
bumetanide 0.5-1.0 mg 
Canada Thiazides@ Loop diuretics 
Netherlands-eBO Thiazides@, e.g. HCT 25-50 mg Loop diuretics 
US-AHCPR Thiazides@, e.g. HCT 25-50 mg loop diuretics, e.g. 
furosemide 10-40 mg 
Netherlands-GP Thiazides@, e.g. HCT 25-50 mg Loop diuretics, e.g. 
furosemide 40~ 120 mg 
US-ACC/AHA Thiazides® Loop diuretics 
._-
---
Maintenance treatment Recommendations about active ti-
in stabilized patientsS tration of diuretic dose 
Thiazides@ Aim at low dose, but preferably no 
complete withdrawal 
Thiazides@ Aim at lowest dose, or withdraw 
Thiazides@ Aim at lowest dose, or withdraw 
Thiazides@ Aim at lowest dose, or withdraw 
Thiazides@ Aim at low dose, but leave stable 
patients at 1 DDD diuretics 
Thiazides@ Aim at lowest dose, or withdraw 
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• Excluding the emergency management of acute heart failure, sif insufficiently effective, thiazides should be replaced by loop diuretics, @Nottobeprescribedincase [ 
of renal insufficiency, AHCPR = Agency for Health Care Policy and Research from the U.S. Department of Health and Human Services, CBO = National Organization 
of Medical Quality Assurance, GP = General practitioners, NHG = Dutch Scientific Society of General Practitioners, ACC = American College of Cardiology, AHA = 
American HeartAssociation, EF = ejection fraction, DOD = defined daily dose, HF = heart failure 
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ACC/AHA guideline no preference for either thiazides or loop diuretics 
is mentioned. The guidelines mention that thiazides should be replaced 
by loop diuretics when the diuretic effect of thiazides becomes insuffi-
cient. Furosemide is by large the most frequently prescribed loop diuretic. 
The dose should be titrated individually and largely depends on the de-
gree of heart failure and the renal response. The recommended number 
of gifts of furosemide per day is one or two. Only the Swedish gUideline 
recommends four gifts per day. All gUidelines recommend active titration 
ofthe dose of diuretics: up-titration when signs of volume overload per-
sist and down titration whenever possible. The target dose is the lowest 
possible dose that prevents volume overload. The Canadian, American, 
and Dutch CBO guidelines suggest an attempt to withdraw diuretic ther-
apy completely after establishment of therapy with ACE-inhibitors. The 
Dutch GP and the Swedish guideline recommend a low maintenance 
dose of diuretics, but complete withdrawal is not advised, not even in the 
absence of symptoms of volume overload. Daily assessments of body 
weight by patients themselves, and instructions about the dosing of diu-
retics or the timing of medical consultation are mentioned as essential 
parts of down titration strategies by the ACC/AHA and the two Dutch 
guidelines. 
Types and dosages of diuretic treatment in severe heart failure with 
persistent oedema (Table 2.4) 
All gUidelines recommend progressively increasing dosages of loop di-
uretics for patients with more severe forms of heart failure with persisting 
oedema. Optimalization of the dose of ACE-inhibitors and the restriction 
of salt intake, and in more severe cases also of water intake, is generally 
recommended to further improve the effect of diuretic treatment. If oe-
dema persists during treatment with high dosages of furosemide (dosages 
varying from IZO mg/day in the Swedish to IOOO mg/day in the Dutch 
CBO guideline are mentioned) addition of a diuretic of the thiazide class 
is generally recommended. The thiazide metozalone is considered by the 
Swedish and the two American guidelines as particularly potent for this 
purpose. Addition of spironolactone is recommended by the Swedish 
guideline, with replacement by a thiazide when it is not effective enough. 
Addition of a combination of ACE-inhibitors and spironolactone in 
furosemide treated heart fail ure patients with persistent oedema is recom-
mended by the AHCPR and the Dutch CBO guidelines. The Canadian 
guideline expresses no preference for the addition of either thiazides or 
spironolactone in these patients. The combination of all three classes of 
diuretics, as an even more potent diuretic regimen, is l11entioned, 
although not explicitly advised, in the Canadian and the Dutch GP 
guideline. Furthermore, the gUidelines mention the usefulness of inci-
dental intravenous administration of loop diuretics if the effect of oral 
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Table 2.4 
Choice of diuretic treatment in severe heart failure with persistent 
oedema 
I Guideline I Consecutive steps' 
Sweden 1 Dose increase of furosemide to 120 mg/day 
2 Addition of spironolactone 25-50 mg/day 
3 Megadoses furosemide (250-4000 mg/day) or addition of 
thiazides (e.g. metalazone intermittently 1-2 days/week) 
Canada 1 Increased dosages of loop diuretics 
2 Combination of diuretics from different classes 
Netherlands-CBO 1 Dose increase of furosemide to 1000 mg/day 
2 Addition of thiazides (e.g. HCT intermittently 2-3 
days/week) 
3 Combinations of loop diuretics and spironolactone 
US-AHCPR 1 Dose increase of furosemide to 160-240 mg twice a day 
2 Addition of thiazides (e.g. HCT intermittently 2-3 
days/week) 
Netherlands-GP 1 Dose increase of furosemide to 500 mg/day 
2 Addition of thiazides 
3 Addition of spironolactone 
US-ACC/AHA 1 Increased dosages of loop diuretics 
2 Addition of thiazides (e.g. metolazone intermittently 2-3 
days/week) 
. Non-pharmacological therapy such as sodium and water restriction, rest, and the avoid-
ance of non-steroidal anti-inflammatory agents are not in this schedule, but are generally 
considered valuable. AHCPR ::: Agency for Health Care Policy and Research from the U. S. 
Department of Health and Human Services, CBO::: National Organization of Medical Qual-
ity Assurance, NHG ::: Dutch Scientific Society of General Practitioners, ACC ::: American 
College of Cardiology, AHA::: American Heart Association, HCr::: hydrochlorothiazide 
administration becomes insufficient as, through a reduction of intestinal 
oedema, this may subsequently cause orally administered diuretics to 
regain effectivity. Bumetanide is a loop diuretic with an equally maxi-
mum effect as furosemide, but its superior gastrointestinal absorption 
may be a relevant advantage in patients with gastrointestinal oedema. 
The Dutch GP guideline advises to replace furosemide by bumetanide if 
gifts with a larger dose than 200 mg furosemide are needed. All gUidelines 
warn against the possible severe plasma electrolyte disturbances caused 
by the administration of combinations of different classes of diuretics 
and recommend frequent laboratory checks. 
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Diuretics in the treatment of heart failure caused by diastolic dys-
function (Table 2.5) 
In diastolic ventricular dysfunction the filling of the heart during the 
diastolic phase is insufficient. This is generally caused by a decreased re-
laxation capability of the muscular wall of the left ventricle. Combined 
systolic and diastolic ventricular dysfunction is common and in elderly 
patients the diastolic component progressively contributes to the clinical 
symptoms of heart failure. It is impossible to discriminate between dia-
stolic and systolic dysfunction on the basis of clinical symptomato-
logy."'" It is suggested that heart failure caused by diastolic dysfunction 
should be treated with drugs that improve relaxation of the ventricle, 
such as IS-blockers and calcium antagonists, while other agents such as 
diuretics, ACE-inhibitors and digoxin should be prescribed in case of 
heart failure caused by systolic dysfunction. 
All guidelines except the US-AHCPR's discuss the treatment of diastolic 
dysfunction. Interestingly, however, the recommendations differ widely. 
With respect to the role of diuretics they range from 'to be avoided"s," to 
(first choice agent'.l3 
Other aspects 
Rellal illsufficiellcy alld diuretics. In case of renal insufficiency, all guide-
lines recommend loop diuretics instead of thiazides. A glomerular filtra-
tion rate or creatinine clearance of <30-40 ml/min is considered to be an 
indication for loop diuretics by most gUidelines. The Dutch GP guideline 
recommends furosemide, whenever serum creatinine levels are above the 
normal range. Adverse effects of diuretics, Hypovolemia is considered an 
important potential side effect of diuretic therapy in all guidelines. Be-
sides (postural) hypotension and renal insufficiency few specific symp-
toms and signs of the hypovolemic state are reported. Hyponatremia can 
be a serious adverse effect and is discussed in all guidelines. The Dutch GP 
and the Swedish guideline present a schedule for the management of 
hyponatremia if it occurs during diuretic treatment. Serum potassium 
levels below 3.5 - 4.0 mmol/l are considered to be an indication for potas-
sium sparing diuretics. Potassium supplements are recommended in the 
US-AHCPR and the Canadian guidelines. ACE-inhibitors are potassium 
sparing, and the combination with potassium sparing diuretics may 
therefore lead to hyperkalemia and should be avoided. Triamterene, 
amiloride and spironolactone are the three available potassium sparing 
diuretics. No preference for one of these three agents is given in the 
guidelines. The dose of potassium sparing diuretics should be titrated 
individually. In the AHCPR guideline, maximum dosages of lOO mg twice 
daily for triamterene and spironolactone, and 40 mg once daily for 
amiloride are mentioned. '3 In contras t to the importance of hypokalemia, 
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Table 2.5 
Diuretics in treatment of diastolic dysfunction 
Guideline Diuretics in diastolic dysfunction 
Sweden To be avoided 
Canada Can be used 
Netherlands·CBO To be avoided 
US·AHCPR Beyond scope of guideline 
Netherlands-GP Equivalent to systolic heart failure 
US·ACC/AHA First choice 
AHCPR::: Agency for Health Care Policy and Research from the U. S. Department of Health 
and Human Services, eBO ::: National Organization of Medical Quality Assurance, NHG ::: 
Dutch Scientific Society of General Practitioners, ACe::: American College of Cardiology, 
AHA::: American Heart Association, HF ::: heart failure 
the relevance of hypomagnesemia as a potential adverse effect is not clear. 
Only the US·AHCPR advises monitoring of magnesium levels in recipients 
of high dosages of diuretics and oral magnesium supplementation if de-
pletion occurs. Unfavourable influences of diuretics on blood lipids and 
glucose are reported in the guidelines, but the clinicai relevance in heart 
failure patients is considered to be limited and no specific measures are 
recommended. Dillretic treatmellt as a diagllostic test. The two Dutch guide-
lines mention the use of test-treatment with furosemide if the diagnosis 
of heart failure is not certain. Subsequent improvement of symptoms and 
signs by the treatment is considered a support for the diagnosis. 
Discussion 
The guidelines 
Carefully designed developmental procedures resulted in six clinical 
guidelines of high quality. The procedures varied between the guidelines, 
butthe adequate use of scientific evidence in combination with extensive 
consensus meetings was the core procedure in all guidelines. In our eyes, 
the American AHPCR guideline reached the highest structural quality. It 
is extensive, very precise, developed by a multidisciplinary working party 
and covers almost all clinical situations. The Swedish and the Dutch CBO 
guidelines were also developed by multidisciplinary working parties, but 
their publications are less cohesive and apparent lack of consensus on 
some of the issues resulted in contradictory recommendations. The 
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Dutch GP guideline was written by general practitioners and focused 
exclusively on patients in the primary care setting. The ACC/AHA and 
the Canadian gUidelines suffer from the fact that they are not 
multidisciplinary, but written by cardiologists exclusively. 
A remark should be made about the role of specialists in the development 
of guidelines to be applied in general practice. Too large influence of 
these specialists may lead to discrepancies between their point of view, 
primarily based on clinical experience with patients referred to hospital 
and the published trials (usually restricted to these patients) and the gen-
eral practitioner's point of view, based on non-hospitalized patients, rep-
resenting a different spectrum of the disease. Since in many countries, 
such as the Netherlands, most heart failure patients are being treated by 
general practitioners, clinical guidelines should ideally be developed by 
a multidisciplinary team (including general practitioners), resulting in 
one national guideline for all physicians. The Dutch solution seems an 
appropriate alternative: guidelines for primary care are written by general 
practitioners and incorporate advice from specialist-experts in the field. 
This may have a positive influence on the acceptance and the implemen-
tation of the gUideline in general practice, although the resulting exis-
tence of two different national clinical guidelines on management of the 
same disease (in at least in part similar patients) is certainly a major disad-
vantage. 
Monotherapy with diuretics? 
A major discrepancy between the guidelines of the Dutch general practi-
tioners and the other guidelines is the recommendation of monotherapy 
with diuretics in heart failure patients who remain without symptoms on 
standard dosages of diuretics. All other guidelines recommend combined 
treatment with diuretics and ACE-inhibitors as standard treatment of 
heart failure. The lack of trials asseSSing the benefit of ACE-inhibitors in 
patients with mild heart failure (New York Heart Association class II) or 
in patients with ejection fractions >40%, and the limited beneficial effects 
reported in subgroups of these patients in the large trials form the scien-
tific background for the conservative recommendations of the Dutch GP 
gUideline. 9.'",",",'3 Furthermore, the Dutch GP guideline mentions limita-
tions of the generalizibility of the results of the published trials to the 
general practice setting, where the prevalence of relatively older patients, 
women, comorbidity, and relatively mild forms of heart failure is higher. 
A final argument for monotherapy with diureticS, as used in the Dutch 
GP guideline is the increasing level of diagnostic certainty during (initial) 
treatment with diuretiCS, which might help to preventneedless treatment 
with ACE-inhibitors of a potentially large group of patients with an un-
certain diagnosis, 
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Types and dosages of diuretics in patients with mild to moderate 
heart failure 
The recommendation in all guidelines to use slow and weaker acting 
thiazides for patients with mild heart failure instead of fast and stronger 
acting loop diuretics seems not in agreement with common medical prac-
tice. In the Netherlands for example, heart failure is generally treated 
with loop diuretics.'6 Recommendations in important pharmaceutic 
handbooks may contribute to this. '4 Active titration of the dose ofdiuret-
ics, as recommended in all guidelines, seems important because both 
under- and overhydration are unwanted conditions with negative effects 
on cardiac function. Thus, continuous monitoring for early signs of 
over hydration combined with periodical down titration of diuretics in 
stable patients is the best strategy for optimal dosing of diuretics. 
The Swedish recommendation of dosing furosemide four times a day is 
not endorsed by references. However, it has a sound theoretical base since 
the duration of the diuretic effect is approximately 6 hours. It might well 
be true that the peak diuresis after a dose of furosemide disappears when 
lower dosages are administered four times a day. Another stipulated way 
to avoid peak diuresis of loop diuretics is to use slow release formulations. 
It should be mentioned, however, that peak diuresis is not disliked by all 
patients. A predictable number of hours per day of strongly increased 
diuresis, may be well acceptable for many patients, providing them more 
convenience during the remaining part of the day (or night). 
Types and dosages of diuretics in severe heart failure with persistent 
oedema 
The guidelines are not unanimous about the treatment of persistent fluid 
retention in patients with severe heart failure. The dose level to which 
furosemide should be up-titrated before adding a diuretic of another class 
varies from 120 mg/day in the Swedish guideline to rooo mg/day in the 
Dutch CBO guideline. Most guidelines recommend addition of a thiazide 
if furosemide alone is insufficiently effective, but the Swedish guidelines 
advises addition of spironolactone. Several studies have demonstrated 
the improvement of heart failure symptoms by additional spironolactone 
in pa tients receiving furosemide and ACE-inhibitors. '5.,6·'''''This remains 
to be established for the addition of thiazides. Extra monitoring is needed 
when combinations of diuretics are administered because of a consider-
able risk of hyperkalemia during loop diuretic/spironolactone therapy, 
and hypokalemia and hyponatremia in loop diuretic/thiazide combina-
tions. These risks may be smaller when the additional diuretics are ad-
ministered intermittently, e.g. every other day. 
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Diastolic dysfunction 
The remarkable differences in the guidelines concerning the role of di-
uretic treatment in heart failure patients with predominantly diastolic 
dysfunction reflect the immatureness of this diagnostic entity. These 
patients need a relatively high preload to ensure optimal filling of the 
ventricle during the diastole. "." Too high dosages of diuretics (and ACE-
inhibitors) may lower the preload to suboptimal levels. This explains the 
recommendations to avoid diuretic treatment in diastolic dysfunction 
found in the literature and in some of the guidelines.',·,8 Clearly, one 
should be reluctant to prescribe diuretics in patients with diastolic dys-
function when no volume overload exists, but if volume overload (e.g. 
pulmonary congestion) develops, diuretics are indispensable. Careful 
judgement of signs of overhydration and underhydration should guide 
titration to optimal dosages. This is not essentially different in diastolic 
and systolic ventricular dysfunction. The differences between the guide-
lines might be explained by this duality. 
Test-treatment with furosemide 
Test-treatment with furosemide, as recommended in the two Dutch 
guidelines, is an interesting but controversial diagnostic tool. A scoring 
list that was used in the Framingham study also included response to 
diuretic treatment as one of the items. '9 The sensitivity and specificity of 
this test-treatment are, however, unknown. One might argue that a good 
response to diuretic treatment (weight loss, less breathlessness, less fa-
tigue, more effort tolerance) pleads in favour of the diagnosis heart fail-
ure, while a negative response indicates that heart failure is absent or that 
heart failure with a Significant forward failure component may be pres-
ent. Although the use of such a test-treatment is pragmatic and based on 
common sense, further studies are needed to assess its diagnostic value 
before its use can be recommended. 
Optimal guidelines? 
In recent years a clear increase in the number of national clinical guide-
lines has occurred. They are potentially important tools with respect to 
quality improvement in medical care. International guidelines such as 
the guideline for the diagnosis of heart failure of the European Society of 
Cardiology30 have several disadvantages. Differences for example in cul-
ture, tradition and economical standards between the home countries of 
the members of the working parties may be obstacles in reaching consen-
sus and often results in insufficiently detailed guidelines. In addition, 
implementation may be less successful than for national guidelines. An-
other problem is the multiplicity of national guidelines per country; e.g. 
one by a governmental initiative, one by a professional organization of 
specialists and one by the national scientific organization of general prac-
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titioners. This clearly is an undesirable situation. It is enough to worry 
about discrepancies between guidelines of different countries, but dis-
crepancies between guidelines within one country will certainly under-
mine the authority and the success of the guidelines. Another vulnerable 
aspect is the updating of existing gUidelines; the needed frequency of 
updates critically depends on new developments in the field. Obviously, 
national clinical guidelines are very important instruments to improve 
the quality of medical care, but more than one guideline per country and 
outdated guidelines should be prevented. 
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3 The current role of diuretic therapy in the treatment of mild to moderate, essential 
hypertension. A critical appraisal of five 
national clinical guidelines 
Introduction 
Hypertension is an important risk factor for cardiovascular disease. ',',3 
The relationship between both systolic and diastolic blood pressure level 
and risk of cardiovascular disease exists at all blood pressure levels.4,5 
Pharmacological treatment of hypertension became common medical 
practice from the beginning of the seventies after the publication of the 
results of the first randomized trials. A substantial number of trials fol-
lowed, and the reduction of cardiovascular morbidity and mortality 
following blood pressure lowering medication became increasingly evi-
dent. 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27 A reduction of 30 - 400/0 in the 
occurrence of strokes and of ro - 20% in the incidence of coronary heart 
disease has consistently and convincingly been demonstrated, The main 
antihypertensive treatment included in these trials were diuretics or IS-
blockers. Remarkably, no results from trials assessing the effect on cardio-
vascular morbidi ty and mortality of the newer classes of antihypertensive 
drugs, such as ACE-inhibitors and calcium antagonists, are available. 
Thus, it seems rather surprising that the newer classes of antih ypertensive 
drugs are being prescribed on such a large scale. Recent surveys in the 
USA and the Netherlands show that of every 100 hypertension patients 
on blood pressure lowering medication, approXimately 25 receive diuret-
ics, 20 IS-blockers, 25 ACE-inhibitors, 20 calcium antagonists, and 10 other 
drugs, (Table 3.1)" Even angiotensine II antagonists, that were introduced 
only very recently, are presently being prescribed at fast increasing rates, 
without any empirical evidence of their capacity to eventually reduce the 
risk of cardiovascular disease. 
Apparently, empirical scientific evidence does not have the impact on 
medical practice it deserves. This may be partly attributable to confusion 
about the drugs of first choice in hypertensive patients, generated by 
numerous, often contradictory, comments continuously appearing in 
(often non-peer reviewed, and drug industry sponsored) periodicals, 
widely distributed among practising phYSicians. Under these circum-
stances national clinical guidelines, developed by independent expert 
committees, may offer a solution by providing solid and unambiguous 
recommendations about diagnostic and therapeutic management to 
practising physicians. The general aim of such gUidelines is improve 
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Table 3.1 
Proportion of different classes of blood pressure lowering drugs pre-
scribed in hypertensive patients in the USA in 1993 (Manolio 95) and in 
the Netherlands in 1995* 
I Class of antihypertensive drugs Proportion (%) 
USA Netherlands 
Diuretics 27 20 
I>-blockers 14 28 
ACE-inhibitors 24 28 
Calcium antagonists 24 15 
Other 10 9 
,., Medische Index Nederland (MIN), Instituutvoor Medische Statistiek (IMS) te Den Haag, 
Nederland BY, personal communication 1996. 
ment in quality of medical care, based on available scientific evidence. 
We studied five currently available national clinical guidelines to review 
the current role of diuretics in the treatment of hypertension. Special 
emphasis was put on the following questions: (I) Ale diuretics still recom-
mended as drugs of first choice in the treatment of hypertension? (2) 
What types and dosages of diuretics are recommended? (3) When are 
potassium sparing diuretics indicated? (4) Is the role of diuretics in the 
treatment of hypertension different in older patients, and (5) What is the 
role of diuretics in hypertension with coexisting disease? 
Methods 
By searching the Medline database on CD-ROM, exploring references 
from relevant publications and by asking experts in the field five national 
clinical guidelines were traced. Only gUidelines published in English, 
German, French or Dutch were sought. We selected only those gUidelines 
published in 1990 or later. Although a European guideline" on hyperten-
sion was published, we did not include international guidelines in this 
study. The available guidelines were scrutinized with respect to our speci-
fied research questions about the role of diuretics in the treatment of 
hypertension. 
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Results 
The guidelines (Table 3.2) 
Five national guidelines on hypertension were studied: two from the 
Netherlands/30,}! one frOlu Canada,32 one frOIn Great Britain,33 and one 
from the USA.34 The first Dutch guideline was developed by the National 
Organization of Medical Quality Insurance (CBO), a fully-government 
sponsored organization. The second Dutch guideline was produced by 
the Dutch College of General Practitioners (GP). The Dutch guidelines 
were published in 1990 and 1991, and thus the results of three major trials 
that came available in 1991 and 1992 could not be taken into ac-
count.'4."'" The US guideline was the 1993 report of The]oint National 
Committee on Detection, Evaluation, and Treatment of High Blood Pres-
sure, from the National Heart, Lung, and Blood Institute. The Canadian 
guideline was the 1993 report by the Canadian Hypertension SOCiety and 
the British guideline was produced by the British Hypertension Society 
in the same year. The Canadian, British, and American guidelines were 
revisions of formerly published versions. 
In all guidelines, governmental or medical professional organizations 
took the Initiative to form a working party of experts with the task to 
write a concept of the guideline. The way these working parties were 
formed varied between the guidelines, as did the procedures for adjust-
ment, approval, publication and implementation of the text. All but one 
of the committees that prepared the guidelines were multidisciplinary. 
Cfable 3.2) Only the Dutch-GP guideline was exclusively written by gen-
eral practitioners, although cardiologists and internists reviewed the 
manuscript and were consulted during a discussion meeting. General 
practitioners were not represented in the committee that prepared the 
British guideline. 
Diuretics as dl'\lgs of first choice in hypertensive patients (Table 3.3) 
All guidelines recommend diuretics as drugs of first choice in the treat-
ment of mild to moderate, essential hypertension. Fourofthe guidelines 
recommend either diuretics or G-blockers as initial drug therapy. Three 
of the guidelines explicitly state that In contrast to G-blockers, diuretics 
are also effective in black hypertensive patients. Only the oldest gUideline 
(Netherland-CBO 1990) includes the possible choice of other classes of 
antihypertensive drugs as initial treahnent. 
If target blood pressure levels are not achieved by the initial therapy, 
three possibilities for additional treatment are generally mentioned: dose 
increment, cOlubination with a drug frOIll another class or 1110notherapy 
with a drug from another class. The American, the two Dutch and the 
Table 3.2 
Characteristics of the five reviewed national guidelines on treatment of mild to moderate hypertension 
Guideline Year of publication Initiative Medical background of authors Target group 
(# of persons in the working party) 
Netherlands-eSO 1990 National Organization of Medi- Internal medicine (9), General practice (3), Car- All physicians 
(CBO 90) cal Quality Insurance (eBO) diology (2), Epidemiology (2), Gynaecology (2), 
Geriatrics (1), Paediatrics (1), Pharmacy (1), 
Public health (1) 
Netherlands-GP 1991 Dutch College of General Prac- General practice (7) General prac-
(NHG 91) titioners (NHC) titioners 
Canada (Can 93) 1993 Canadian Hypertension Society Internal medicine (5), Cardiology (1) AI! physicians 
Great Britain 1993 British Hypertension Society Internal medicine (5), Clinical pharmacology All physicians 
(Seever 93) (1), Epidemiology (1) 
USAUNCV93) 1993 Joint National Committee on Internal medicine (10), General practice (1), All physicians 
Detection, Evaluation, and Pharmacy (1) 
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Table 3.3 
Recommendations about the drug of first choice for patients with mild 
to moderate hypertension 
Guideline First choice treatment Additional treatment to reach 
target blood pressure 
Netheriands·CSO Diuretic, g-blocker, ACE· Increase drug dose, substitute 
inhibitor or calcium an- with another drug, or combine 
tagonist drugs 
Netherlands-GP Diuretic or g-blocker Increase drug dose, substitute 
with another drug, or combine 
drugs 
Canada :? 60 y: Diuretic ~ 60 y, consecutive steps: 1) 1\-
< 60 y: Diuretic or I!.- blocker 2) Combination diuretic 
blocker and B-blocker 
< 60 y, consecutive steps: 1) 
Substitute with other first choice 
drug 2) Combination of first 
choice drugs or monotherapy 
with another class of drugs 3) 
Other combinations 
Great Britain Diuretic or I!·blocker No recommendations in the 
gUideline 
USA Diuretic or R-blocker Increase drug dose, substitute 
with another drug, or combine 
drugs 
British guidelines consider these three possibilities to be equally effective, 
while the Canadian guideline recommends to first interchange diuretics 
and B-blockers, then combine these two classes, and finally prescribe 
monotherapy with a drug from another class. 
Type and dose of diuretics (Table 3.4) 
The most widely recommended diuretics are hydrochlorothiazide and 
chlorthalidone. The American, Canadian and two Dutch guidelines all 
recommend hydrochlorothiazide or chlorthalidone. The British guideline 
does not mention any of the thiazides in particular. Other thiazides men-
tioned in at least one of the guidelines include chlorothiazide, bendro· 
flumethiazide, indapamide and metolazone. Daily dosages of I2.5 to 50 
mg hydrochlorothiazide or chlorthalidone are uniformly recommended, 
usually in one gift per day. In hypertensive patients with renal insuffi-
ciency loop diuretics instead of thiazides are recommended in the US 
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Table 3.4 
Recommendations about type and dose of diuretic in the treatment of 
mild to moderate hypertension 
Guideline Type of diuretic Daily dose # of gifts 
(mg) per day 
Netherlands-CSc Hydrochlorothiazide, 12.5-50 lor 2 
chlorthalidone, 25-50 1 
chlorothiazide or 250-500 1 or 2 
other thiazide 
Netherlands-GP Hydrochlorothiazide, 12.5-25 1 
chlorothiazide or not stated not stated 
bendroflumethiazide 2.5-5 1 
Canada Hydrochlorothiazide, 12.5-50 1 
chlorthalidone, 12.5-25 1 or EOD 
indapamide or 2.5 not stated 
metolazone 2.5-5 not stated 
Great Britain Thiazides, not specified not stated not stated 
USA Hydrochlorothiazide, 12.5-50 1 
chlorthalidone or 12.5-50 1 
other thiazide 
EDD = Every other day 
guideline and the Dutch-CBO guideline. The other guidelines do not 
mention loop diuretics, implying that B-blockers or one of the newer 
antihypertensive agents are indicated when contraindications for thia-
zides exist. 
PotassiuIll sparing diuretics 
None of the guidelines recommend potassium sparing diuretics or combi-
nations of potassium sparing diuretics and non-potassium sparing diuret-
ics as initial therapy in hypertension. Nevertheless, all guidelines advise 
to add potassium sparing diuretics in case of potassium depletion, and 
the American and Canadian guidelines mention potassium suppletion as 
an alternative. Remarkably, however, recommendations for laboratory 
checks and cut-off levels of acceptable plasma potassium are not given. 
The British and the Canadian guidelines consider potassium sparing com-
binations a possible first choice therapy in elderly hypertensive patients. 
Further, the Canadian guideline recommends potassium sparing combi-
nations if dosages larger than 2S mg/day hydrochlorothiazide (or the 
eqUivalent of another thiazide) are required. In the Dutch-GP guideline 
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increased risk of arrhythmias (i.e. patients with coronary artery disease, 
cardiomegaly, heart failure, or digoxin treatment) is considered an indi-
cation for potassium sparing diuretic combinations. No recommenda-
tions about the type and dose of potassium sparing diuretics are given in 
the guidelines, with one exception: the Dutch-GP guideline prefers 
trianlterene. 
Antihypertensive therapy in the elderly 
Some of the guidelines express strong preferences of diuretics over alter-
native antihypertensives, and notably Il-blockers, in elderly patients. The 
Canadian guideline states that diuretics are the only drugs of first choice 
in the elderly, and the British guideline mentions a clear preference of 
diuretics over Il-blockers. Potassium sparing diuretic combinations are 
recommended more explicitly for the elderly in the British and the Cana-
dian guidelines. Finally, all five guidelines suggest the use of lower initial 
dosages in older patients. 
Diuretic antihypertensive therapy and coexisting disease 
All gUidelines include specific therapeutic advices for hypertensive pa-
tients with coexisting diseases. I n patients with congestive heart failure, 
most guidelines prefer diuretics (and ACE-inhibitors). In case of diabetes 
mellitus, four of the five guidelines recommend to avoid diuretics as 
drugs of first choice, and 'if'. diuretics have to be added, to closely moni-
tor blood glucose levels. Hyperuricemia is not considered a contraindica-
tion for thiazides by any of the guidelines, unless symptoms of (recur-
rent) gout are present. The recommendations for patients with dyslipi-
demia are more contradictory. The American, British and Dutch-CBO 
guidelines recommend avoidance of diuretics in these patients, whereas 
the Canadian and Dutch-GP guidelines explicitly state that dyslipidemia 
is no reason to follow a different treatment policy. 
Discussion 
The guidelines 
Carefully designed procedures for development resulted in guidelines of 
high quality. The various steps of the procedures were different, but the 
adequate use of scientific evidence in combination with extensive con-
sensus procedures was the core element in all countries. The most exten-
sive and precise recommendations were provided by the American and 
Canadian guidelines. 
International guidelines such as the Hypertension Guidelineofthe World 
Health Organization and the International Society of Hypertension29 
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have several disadvantages. Differences for example in culture, tradition 
and economical standards between the home countries of the members 
of the working parties may be obstacles in reaching consensus and often 
results in insufficiently detailed gUidelines. In addition, implementation 
may be less successful than for national guidelines. 
Because most hypertension patients are treated in general practice, in-
volvement of GPs in the development of hypertension guidelines is es-
sential. One national guideline for all physicians written by a broad 
multidisciplinary working party, including general practitioners, seems 
the most desirable option. As in the heart failure guidelines discrepancies 
between the characteristics of patients treated by specialists and GPs may 
generate unsurmountable differences in opinion. Nevertheless, the grow-
ing tendency to consider the entire spectrum of hypertensive patients by 
both specialist and GP-experts in hypertension in the Netherlands is re-
flected by a recent proposal for adjustments ofthe gUidelines.3S It seems 
onlya matter of time until the undesirable situation of two national hy-
pertension guidelines in one country will cease to exist. 
Thiazide diuretics are first choice 
All guidelines recommend thiazides as drugs of first choice in the treat-
ment of hypertension, unless specific conditions require other antihyper-
tensive medications. Beta-blockers are usually considered an equally ef-
fective alternative for diuretics: second in line in elderly patients and 
when heart failure is present, but first in line when cardiac protection 
against ischemic events is indicated (e.g. in those with a history of myo-
cardial infarction or angina). 
Remarkably, the fifth edition of the American guideline" recommends 
either diuretics or R-blockers, whereas in the preceding edition ACE-in-
hibitors, calcium antagonists and a-blockers were also included as first 
choice antihypertensive medications. This is not surprising in view of the 
evidence from clinical trials. The main antihypertensive drug in eighteen 
of the 22 available randomized controlled trials was a thiazide diuretic. 
The overwhelming body of evidence that antihypertensive treatment is 
beneficial, is largely based on studies with diuretics. The current lack of 
long-term studies of the newer classes of antihypertensive drugs is strik-
ing. Several large trials with ACE-inhibitors and calcium antagonists are 
underway. The recent commotion about the safety of nifedipine in hy-
pertension illustrates the need to be cautious with drugs until results 
from large trials are available.36•37 
PotassiuIll sparing diuretics? 
In all guidelines information and recommendations on indications for 
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potassium-sparing diuretics is scarce. Three important trials with potas-
sium sparing diuretics as main treatment in elderly hypertensives showed 
impressive reduction in the incidence of stroke and coronary heart dis-
ease. 19,25,27 Furthernl0re, two recent case· control studies denlonstrated an 
increased incidence of sudden cardiac death in patients treated with non-
potassium sparing diuretics compared to potassium sparing diuretic com-
binations.38,39 Based on this scientific evidence, one could argue that 
beside monotherapy with thiazides, a combination of a thiazide and a 
potassium-sparing diuretic should be considered therapy of first choice 
in hypertensive elderly patients. Non-potassium-sparing diuretics remain 
preferable in patients with renal insufficiency, concomitant treatment 
with ACE-inhibitors, or demonstrated hyperkalemia. 
Diuretics in dyslipidemia and diabetes mellitus 
The guidelines differ considerably concerning the rated value of diuretics 
in dyslipidemic patients, The Dutch-GP guideline and the Canadian 
guideline do not advise against thiazide therapy in these patients, in con-
trast to the other three guidelines, Thiazide therapy increases cholesterol 
level by approximately 3%, and this seems not to be a transient phenom-
enon!o Although this small increase may not seem clinically relevant in 
individual patients, it is not neglectable at the population level. Never-
theless, it should be stressed that the trials have demonstrated the bene-
fits of thiazides, even when cholesterol levels may have offset a small part 
of this favourable effect. 
The role of thiazides in patients with diabetes mellitus, remains contro-
versial. Randomized trials assessing the long-term effect of diuretics or 
other medications in diabetic hypertensive patients on cardiovascular 
disease are not available, whereas several studies reported disadvanta-
geous efIects of thiazides on parameters of lipid and glucose metabolism, 
and advantageous effects of ACE-inhibitors on several relevant interme-
diate outcomes, such as renal function!',42,43,44,4S In view of this evi-
dence, the predominant recommendations in the guidelines to initially 
prescribe a non-diuretic drug, such as ACE-inhibitors or calcium antago-
nists, and to monitor glucose levels in case diuretics are required in dia-
betic patients, is understandable. 
Conclusions 
In the current national clinical guidelines thiazide diuretics are recom-
mended as drugs of first choice in the treatment of hypertension. In mid-
dle-aged patients g-blockers are an eqUivalent alternative. The fact that 
despite strong recommendations in all guidelines to prescribe thiazides 
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or B-blockers, prescriptions of ACE-inhibitors, calcium antagonists and 
other agents constitute approximately 50%of all current prescriptions in 
hypertension is remarkable and regrettable. The impact of national 
guidelines can obviously be further improved. 
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4 Studies on withdrawal of medication: methodological aspects 
Introduction 
Many patients receive long-term drug therapy. Heart failure and hyper-
tension are examples of conditions that may lead to drug use over pro-
longed periods. In clinically stable asymptomatic patients on drug treat-
ment, withdrawal of therapy could be considered. Criteria to guide with-
drawal of long-term medication in selected patients should not only be 
based on clinical experience, but also on knowledge about prognostic 
implications of withdrawal, provided by solid experimental studies. 
Attempts to decrease the number of patients who are on unnecessary 
long-term drug treatment will probably be encouraged by the availability 
of results from clinical trials. It is laudable that in recent years the num-
ber of reports of studies assessing the possibility of withdrawal of medica-
tion is increasing. They have been published in a variety of medical fields: 
for example nursing-home medicine, ',',3 cardiology, 4,5,6 and general prac-
ticeJ,S,9tIO,II Sonle of these studies are uncontrolled or nOllRrandonlized, 
while others are randomized controlled trials (RCTs). The latter are uni-
versally accepted as the paradigm to assess treatment efficacy and one of 
the questions to be addressed in this paper is whether drug withdrawal 
studies need to be designed as randomized, controlled, double-blind 
trials, or whether methodologically iess stringent study designs are rea-
sonable alternatives. 
Very few literature references on the methodology of drug withdrawal 
trials are currently available. De ]onge describes some methodological 
issues in his thesis and Pocock pays attention to the methodology of so-
called 'negative trials', one of the features of withdrawal studies."'" It 
may be anticipated that more drug withdrawal studies will be conducted 
in the forthcoming years and in our view more attention should be payed 
to the specific methodological aspects of drug withdrawal studies. The 
aim of this paper is to highlight a number of these methodological issues, 
with special emphasis on the aim/research question, design and data 
analysis, 
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Aim and research question 
Drug withdrawal studies aim at assessing the possibility and effects of 
reducing unnecessary drug therapies. Typically, the main research ques-
tions addressed in these studies are: (1) What proportion of patients can 
be successfully withdrawn from treatment, (2) What are the (short- and 
long-term) effects of drug withdrawal, and (3) What are predictors for 
successful withdrawal? Thus, the principle outcome in drug withdrawal 
studies is the proportion of long-term drug users that can be successfully 
withdrawn from treatment. 'Successfully' should be strictly defined by 
criteria that were determined in advance and typically implies: without 
worsening of clinical condition or prognosis. 
Drug efficacy in withdrawal studies? 
Sometimes a tendency occurs to use results from drug withdrawal studies 
to draw conclusions regarding a drug's efficacy. In other words: harmful 
clinical effects of withdrawal of a drug are interpreted as proof of poten-
tial beneficial effects of the same drug when initiated in previously un-
treated patients. An interesting example of an early drug withdrawal 
study is The Sixty Plus Tria!." In this study postmyocardial infarction 
patients on long-term therapy with con marin were randomly allocated 
to a withdrawal group and a control group in which therapy was contin-
ued. The incidence of myocardial infarction was lower in patients that 
continued coumarin therapy and the authors concluded that (1) the 
harmful eflect of withdrawing coumarines was demonstrated, and that 
(2) extrapolations regarding the efficacy of the treatment per se were not 
possible. Nevertheless, the trial results were generally seen as an endorse-
ment of the efficacy of coumarl ns in secondary prevention of myocardial 
infarction. We believe (with the authors) that the latter conclusion is 
unjustified, mainly because, inherent to all drug withdrawal shldies, pa-
tients who did not initially respond to the treatment or who developed 
side effects during treatment are very unlikely to have become chronic 
users and thus to be included in the study. In addition, potential rebound 
effects preclude extrapolation of results from withdrawal studies to drug 
efficacy. An extreme example of the latter is morphine: unsuccessful 
withdrawal for sure does not allow conclusions concerning the efficacy 
of morphine. Although most drugs have less profound rebound effects, 
complete absence of rebound phenomena can never be excluded. 
Drugwithdrawal studies are sometimes specifically designed to Shldy the 
efficacy of a drug. In such studies, the medication is initially given to all 
eligible patients. This run-in phase on active medication is used to titrate 
the dose of the medication to optimal levels and identify non-compliers. 
After randomization one arm has its treatment withdrawn, while the 
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other patients continue to receive the drug. It is important to realize that 
the intervention in these trials is not the withdrawal of a drug as such, 
but that successive initiation and withdrawal of the drug are one com-
posed intervention. In this design, the problem of preselecting good re-
sponders and patients with no major side effects is made somewhat more 
controllable by the availability of these data for all eligible patients. The 
biological problem of unknown rebound effects however, is not preven-
ted and conclusions on drug efficacy remain illusive. Such study deSigns 
are used by certain research groups as an alternative for regular ReTs, and 
were first described by Amery and Dony in 1975. '5 111e number of pub-
lished reports of drug withdrawal studies with an efficacy aim is increas-
ing. Remarkably, many are being performed in the field of cardiology, 
mainly studying the effects of withdrawal of drugs from patients with 
heart failure. 16,l7,18,I9 
Study design 
The paradigm of drug efficacy studies is the randomized, double-blind 
trial. It is therefore remarkable that in studies assessing the effects of 
withdrawal of medications often less stringent designs are applied. 
Nonexperimental (Le. observational) studies to assess effects of drug with-
drawal are theoretically possible, although, as in nonexperimental effi-
cacy studies, there are major methodological limitations. One could 
think of retrospective queries or explorations of medical files of patients 
who had their medication withdrawn by phYSicians trying to cut down 
overmedication. To our knowledge, however, no such observational stud-
ies have been published. 
Studies with an experimental design are less prone to biases. The most 
unpretentious are withdrawal studies with uncontrolled patient series, 
which can be efficient eye openers. Many of such studies have been pub-
lished and some examples are in the list of references.7,s.9,w,,, Interest-
ingly, and understandably, the conclusion of these studies is always simi-
lar: 'a larger and controlled trial is needed to verify the reSUlts'. A compari-
songroujJ in experimental designs is needed to discriminate the net result 
of an intervention from effects such as natural course of disease or regres-
sion to the mean. 
Further, random al/ocation of patients to two (or more) trial arms is a man-
datory procedure to ensure comparability of prognosis between the inter-
vention group and the control group. This holds in drug withdrawal stud-
ies as well as in other experimental studies. 
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One could argue whether the use of placebo medication in the withdrawal 
group is a necessary feature of drug withdrawal studies. The purpose of 
placebo is elimination of the influence of extraneous effects (the placebo 
effect). In drug efficacy trials, prior belief of patients or doctors in benefi-
cial effects of a new treatment may result in positive (but non-pharmaco-
logical) treatment effects; the so called placebo effect. Analogously, prior 
belief of patients in harmful effects (of drug withdrawal) may result in so-
called nocebo effects. Nocebo refers to unpleasant in contrast to placebo 
which refers to pleasant. 22,23 
In an open design, extraneous effects can only partly be eliminated. Ef-
fects, such as getting used to the study setting, coinciding interventions, 
and extra attention of doctors are more or less controlled for by the avail-
ability of a control group, but prior expectations of the effects of cessa-
tion of therapy by both patients and doctors, may easily result in addi-
tional effects. 
When the purpose is to assess the effect of withdrawal of the pharmaco-
logical substrate, all other effects are considered extraneous and thus 
blinding of patients and doctors is required. This can be achieved in drug 
withdrawal studies when patients in the control group are maintained on 
active drugs (=verum), whereas the withdrawal group is treated with pla-
cebo. These studies actually are not placebo-controlled but verum-con-
trolled. Another major advantage of placebo medication is the possibility 
of blilldillgwith, consequently, avoidance of potential information bias 
at measuring trial outcomes. 
One could take a more pragmatic approach and not study the isolated 
pharmacological effect of drug withdrawal as the intervention of interest, 
but the effect of the procedure of withdrawing the drug as a whole. Then, 
the possible additional effects mentioned above are not considered extra-
neous. Some suggest this would be more in line with every day medical 
practice in whidl the gross success rate of withdrawal of medication is 
more important, and the underlying cause (withdrawal of pharmacologic 
substance or extraneous effect) is relatively irrelevant. In those cases an 
open design is feasible. A major disadvantage is the above mentioned 
possibility of information bias, notably in measurements of outcome 
parameters prone to subjective interpretation. The use of harder out-
comes may, however, limit this problem. 
Several additional arguments in favour of a blinded design should be 
mentioned. First, the availability of data about the isolated pharmaco-
logic effect provides more insight in the nature of the events occurring 
after c1rugwithdrawal than data that mix up pharmacological effects with 
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extraneous effects. This is important because patients on long-term medi-
cation often have gradually evolved the belief that taking the drug is an 
essential part of their health promoting behaviour and as a consequence 
withdrawing their tablets may easily result in reinitiation of therapy, 
which, however, may be largely caused by their fear to have their tablets 
withdrawn. Itseems preferable to first assess the isolated pharmacological 
effects of drug withdrawal, preferably by blinding procedures and includ-
ing placebo therapy. Subsequently, open studies on the effect of the pro-
cedure of cessation of therapy may provide important additional infor-
mation. 
Blinding is technically more complicated in drug withdrawal studies then 
in RCTs because of two reasons. First, blind down titration of the dose, 
generally mandatory to avoid or diminish rebound effects, is not as sim-
ple as blind up-titration in efficacy RCTs. In the latter case the boxes of 
study medication contain either the active drug or placebo and up-titra-
tion can simply be effectuated by increasing the dose of 'study medica-
tion', no matter if it is active or placebo. An analogous procedure for 
down titration in a drug withdrawal trial would result in dose reductions 
in the control group and sudden withdrawal in the index group, which 
of course is undesirable. To solve this problem, separate 'dose reduction' 
boxes should be added to the study medication package. Combinations 
of low dose tablets of active and placebo preparations can be used to real-
ize the desired down titration schedules. Second, extra effort should be 
put in assuring complete similarity of active and placebo study medica-
tion (form, colour, taste, consistency), because there is an increased prob-
ability of recognition of the character of the tablets in combined sets 
with consequently breaking of the randomization code. Moreover, a pa-
tient's acquaintance of the drug effect can impair the success of the 
blinding procedure, because the patient has been using the drug for a 
prolonged period. For these reasons challenging the effectiveness of the 
blinding procedure during the course of the trial is more essential in drug 
withdrawal studies then in efficacy studies. This may be done by asking 
the patients (and the investigators) during the follow-up examinations 
to guess the nature of the study medication and to present these results 
in the report of the trial. 
Study population 
Knowledge of the characteristics of the study population included in a 
trial is important for the generalisability of the study results. Drug with-
drawal studies differ from efficacy RCTs with respect to the composition 
of the patient population. Long-term drug use, the main inclusion crite-
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rium, may lead to a considerable level of diagnostic heterogeneity of the 
patient population, because medication may have been prescribed for 
different initial diagnoses and retrospective data about the indications of 
initiation of therapy are usually difficult to obtain. High blood pressure 
is an example of a condition in which long-term dmg treatment is not 
always justified by an adequate diagnosis. Premature start of treatment 
might easily explain a relative high proportion of successful withdrawals, 
while on the other hand contamination of the study population with 
patients with heart failure may have an opposite effect. 
Generally, chronic medication will be prescribed at regular intervals by 
the treating physicians, and thus patient recruitment may take place dur-
ing these consultations. Alternatively, potentially eligible patients may 
be actively approached. In the Netherlands this is generally possible be-
cause of the availability of a file of patient names of long-term drug users 
In registries of pharmacies or general practitioners. The advantage of us-
Ing pharmacy registries is that initial recruitment is relatively indepen-
dent from the treating physicians. This may limit selectivity of inclusion 
and increase generalisability of the trial results. 
Refusal of patients to cooperate is another factor that may negatively 
influence the success of patient recruitment and limit generalisibility of 
the results. In withdrawal studies patients may readily perceive the sug-
gested intervention as possibly harmful, especially if not proposed by 
their own treating phYSician, who in most cases initiated and continued 
the long-term medication. For this reason an active approach of patients 
by investigators may provoke unwillingness to cooperate and careful 
back up by treating physicians is essential. In our studies on withdrawal 
of diuretic treatment in elderly patients, potentially eligible patients (pre-
selected with the aid of pharmacy registries) were first approached by 
their general practitioner and the rate of patient refusal was low (I5%). 
Finally, in drug withdrawal studies the stable clinical baseline condition 
(without symptoms) of eligible patients may result in a higher number 
of refusals by patients or vetos by treating physicians in comparison to 
efficacy trials, where eligible patients generally are In need of a treatment. 
Duration of follow-up period 
A specific feature of drug withdrawal studies is that no difference in out-
come between the patients withdrawn from therapy and those who con-
tinue to receive medication is anticipated. In other words, the prior hy-
pothesis is that the drug under study might be withdrawn in a large pro-
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portion of patients without unfavourable clinical effects. At this point it 
is essential to introduce the term 'negative trial' .'3 Negative trials are trials 
with a prior expectance of 'no-difference' between the comparison 
groups. Drug withdrawal studies are an example of such negative trials. 
Another example are trials that aim to demonstrate equal efficacy (with 
fewer adverse drug reactions) of newly developed drugs and 'classical 
drugs'. This feature of drug withdrawal studies has consequences for the 
length of the follow-up period as well as for the required trial size. If a 
specific elIect shortly after the intervention is expected, e.g. change of 
blood pressure after initiation or cessation of antihypertensives, one 
could decide to keep the follow-up period short. But if no effect is antici-
pated, as generally in withdrawal studies, a relevant follow-up period 
after which one could conclude that 'successful withdrawal' has been 
achieved should be chosen. Thus, in negative trials the length of the fol-
low-up period is an essential part of the definition of the principle out-
come 'successful withdrawal'. Another reason to include relatively long 
follow-up periods in drug withdrawal studies is the occurrence of 
rebound effects'" or long lasting effects (e.g. slow return of hypertension 
after withdrawal of thiazides). In drug withdrawal studies the tendency 
exists to plan follow-up periods that are shorter than desirable. The fol-
low-up period in randomized, controlled, blinded withdrawal studies 
published until now ranges from 3 to 24 months, which seems rather 
short, both in comparison to drug efficacy studies and in view of poten-
tial rebound effects and long-term unfavourable effects of cessation of 
therapy. 
Trial size 
A false positive statistical test is called a type I error, whereas a false nega-
tive test is called a type II error. In drug efficacy RCTs type I errors are 
more serious than type II errors, because the former may cause more pa-
tients to be exposed to useless, and possibly harmful, treatment. Type II 
errors generally have less important implications: a potentially beneficial 
treatment might be missed but the principle 'primam non nocere' is any-
how respected. This is why in RCTs it is more important to avoid type I 
than type II errors, which is reflected by the commonly chosen magni-
tude of the statistical parameters a and B of 0.05 and 0.1, respectively. In 
drug withdrawal studies one hopes to demonstrate that withdrawal of a 
drug has 'no' elIect and thus the anticipated outcome is: no difference 
between the intervention and the control group. Type I errors in these 
trials lead to an erroneous conclusion of the existence of a difference 
between the studied groups with equally important clinical consequences 
as type I errors in efficacy RCTs, namely unjustified (continued) use of 
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long-term medication. 'lYpe II errors in drug withdrawal studies lead to 
an erroneous confirmation of 'no difference', and may possibly have 
even more serious clinical consequences (unjustlfied drug withdrawal in 
many patients) then type I errors. Thus, the avoidance of type II errors in 
drug withdrawal trials is more important than in efficacy RCfs and con-
sequently the value of E should be larger in drug withdrawal studies. The 
magnitudes of a and E depend on clinical judgements about the risks of 
withdrawing effective medication or continuing unnecessary, possibly 
harmful medication. The choice of smaller values of E together with an 
unaltered value of a will result in larger sizes of drug withdrawal studies 
compared to efficacy trials. 
As mentioned earlier, drug withdrawal trials are negative trials and for 
negative trials an adapted method to determine trial sizes has been de-
scribedY·"In this case the reasoning is based on predefining the size of 
theIOox(I-a)%confidence interval of the difference in percentage success 
(or risk) between the two treatments and predefining the acceptability of 
the chance (E) that this CI will be exceeded. The choice of the magni-
tudes of both a and f!, is again based on the acceptability of the clinical 
consequences of erroneously interpreted trial results and again, drug 
withdrawal trials appear to be in need of larger trial sizes, no essential 
difference between this method and the one described in the foregoing 
paragraph. 
The smaller the clinical effect one wishes to exclude, the larger the trial 
size needed. The decision about acceptable clinical effect sizes wiII be 
influenced by the fact that drug withdrawal trials include patients in a 
stable clinical condition, and thus not much harm will be acceptable. 
Thus, smaller effects usually are of interest than in efficacy RCTs, which 
deal with patients whose condition need treatment or at least a preven-
tive action. As a consequence, this is another reason why drug with-
drawal trials generally require larger trial sizes, apart from the Influence 
of the choice of a and E. 
Data analysis 
When many patients drop-out during the follow-up period of a RCI; loss 
of comparability of prognosis between the trial arms becomes a realistic 
problem. Intention-to-treat analysis is the most widespread method, ap-
plied to neutralize potential bias by selective drop-out of patients. The 
motives for intention-to-treat analysis of the principle outcome do not 
differ between drug withdrawal studies or efficacy RCTs. However, the 
choice of the principle outcome may lead to a rather different sihlation 
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in drug withdrawal studies. Unsuccessful withdrawal of treatment in it-
self may very well be the major reason for drop-out, but it is at the same 
time the principle outcome. This simplifies the matter indeed, intention-
to-treat analysis for the principle outcome becomes easier because the 
number of unwanted drop-outs is substantially decreased. 
Also for secondary outcomes (e.g. change in blood pressure after with-
drawal of antihypertensive therapy) analysis according to the intention-
to-treat principle is preferable. Patients who satisfy the criteria for the 
principle outcome of the study, however, will generally have resumed 
their original treatment and including data in the analysis, after reini-
tiation of the treatment (e.g. blood pressure after resuming antihyperten-
sive therapy) would lead to irrelevant conclusions, certainly if large num-
bers of patients resumed therapy as is often the case in withdrawal stud-
ies. To describe the changes in secondary outcomes (such as blood pres-
sure) during the follow-up of the trial two analytic techniques may be 
applied as alternatives to the intention-to-treat analysis: r) carry-forward 
analysis, in which the last available data (before treatment had been re-
sumed) are carried forward until the end of the study follow-up period, 
and 2) separate analysis of patients who were successfully withdrawn 
from treatment and those who were not. 
Choice of effect measure 
In ReTs risk ratios and -differences are the most frequently used effect 
measures. Statistically, ratios are preferable when the magnitude of an 
outcome is proportionally related to its baseline value and differences if 
such a relation does not exist." In this respect efficacy RCTs and with-
drawal studies are similar. However, the magnitude of effects in with-
drawal studies tends to be larger, which leads to a less frequent occur-
rence of the proportionality of relations between outcome magnitudes 
and their baseline values, and consequently to a more frequent use of 
differences instead of ratios as effect measures in drug withdrawal trials. 
Risk difference and risk ratio address 'risk' (of disease), whereas essentially 
the interest of withdrawal studies is 'success' (of withdrawal of therapy). 
To more directly denominate the proportion of patients that may be suc-
cessfully withdrawn from medication, an effect measure of 'success' 
would be preferable. In uncontrolled, but also in several controlled with-
drawal studies, the proportion of patients in the withdrawal group that 
is successfully withdrawn is often considered the 'success rate'. This rate, 
however, does not take into account the proportion of withdrawn pa-
tients, in which reinitiation of therapy is not attributable to withdrawal 
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of the pharmacon, but to natural history of the underlying disease or 
nocebo effects. This latter proportion can only be assessed in placebo-
controlled withdrawal trials, (Figure 4.1) and is equivalent to the propor-
tion of patients in the control (=venn11) group that requires intervention 
because of worsening of their clinical condition. Thus, an 'adjusted suc-
cess rate', i.e. the sum of this proportion and the 'success rate' in the 
withdrawal group, can be calculated. This effect measure is equivalent to 
lone minus the risk difference', where risk difference is the difference in 
risk of clinical deterioration in the two comparison groups. The clinical 
meaning of this effect measure is the proportion of patients in which 
withdrawal of the phan11acon per se, has no adverse eflect on the pa-
tient's clinical condition. 
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Adjusted success rate as a measure of successful withdrawal of long·term medication. 
In Table 4.1 the 'adjusted success rates' from seven controlled studies on 
withdrawal of diuretics are calculated and compared to the, usually re-
ported, success rate in the withdrawal group. Comparison ofthese 2 mea-
sures provides additional insight in the clinical consequences of with-
drawal of a pharmacon. 
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Table 4.r 
Adjusted success rate, calculated from the results of randomized con-
trolled trials of withdrawal of diuretic therapy. 
Author! Control group Withdrawal group 
group Success Success on placebo 
on active 
treatment 
('Yo) ('Yo) 
Elderly patients on long-term diuretic therapy 
Burr' 92 76 
Myers 2 79 71 
Walmas 87 51 
Hypertension 
Veterans25 96 15 
Maland(HDFP)' 84 58 
MRC' 80 50 
Freis(Veterans)26 73 31 
• Adjusted success rate = (1 - Risk difference) 
S This thesis, chapter 7 
Conclusions 
Adjusted. suc-
cess rate 
('Yo) 
84 
92 
64 
19 
74 
70 
58 
Drug withdrawal studies should be designed as carefully as any other 
study on drug effects (e.g. drug efficacy studies) and the methodological 
demands are equally rigorous. Patient populations in drug withdrawal 
studies are less homogeneic and difficulties with inference to larger popu-
lations may occur. The outcome of interest is the proportion of patients 
which can be successfully withdrawn from treatment. Conclusions about 
efficacy of a drug, by extrapolation and reversal of withdrawal effects, 
however, are not possible. Criteria for successful withdrawal should be 
carefully defined in advance. Follow-up periods tend to be too short in 
published drug withdrawal trials, although relatively long follow-up peri-
ods are required to assess rebound effects and long-term effects of with-
drawal. The need for placebo treatment and blinding is influenced by the 
decision whether other effects than cessation of administration of the 
pharmacon are considered extraneous and the pOSSibility of information 
62 Dillretic tllerapy: Cllrrellt role alld effects o(witlldrmval 
bias. Trial sizes need to be larger, mainly because of the importance of 
avoiding both type I and type II errors. Intention-to-treat analysis maybe 
substituted by carry forward analysis or separate group analysis in the 
study of secondary outcomes. Effect measures of 'success' may provide 
better insights in the clinical relevance of the results of withdrawal trials 
than 'risk' effect measures. 
Double-blind, (verum-)controlled, randomized drugwithdrawal trials are 
feasible, and if well designed they may be an important tool to learn 
when overmedication can be curtailed. 
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5 Accuracy of an oscillometric automatic blood pressure device: 
the Omron HEM403C 
Introduction 
The mercury manometer Is generally accepted as the standard Instrument 
to measure blood pressure in medical practice. Automatic blood pressure 
measurement devices are frequently used by patients for self-measure-
ment at home. The simplicity of the measurement procedure is an advan-
tage of the automatic devices over mercury manometers. This makes 
them more suitable for self-measurement. The elimination of observer-
related sources of error, such as expectancy bias, terminal digit preference 
and parallax Is another attractive feature of these devices and is the main 
reason for the frequent use of automatic devices in clinical trials. 
The current automatic devices generally apply the oscillometric method. 
Pressure oscillations In the air cuff of the device, which arise from the 
expansion of the arm by the blood pressure increase at each heart beat, 
are recorded by a pressure sensor and systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) are calculated from the osclilation pattern 
by a microprocessor that uses a specifically developed software protocol.' 
The method is relatively insensitive to disturbing noises compared with 
the auscultatory method. A fundamental difference with the conven-
tional auscultatory method is that the auscultatory method is based on 
the detection of Korotkoff sounds and the oscillometric method on the 
analysis of a pressure oscillation pattern. This has given rise to questions 
about the agreement of both methods in individual patients. One should 
recognize that agreement between blood pressure devices can be quite 
acceptable at average in large patient groups, and at the same time be 
inferior in subgroups of patients or in individual patients, notably when 
the measurement principles of the devices are fundamentally different. 
This underlines the need for a carefully designed validation procedure. 
The Omron HEM403C is (in 1993) by far the most frequently used auto-
matic blood pressure device in general practice in the Netherlands. Thus, 
an assessment of its accuracy is warranted. We are currently using the 
Omron HEM403C in the setting of a randomized clinical trial, which 
further urged us to determine its accuracy. 
The objective of our study was to assess the accuracy of the Om ron 
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HEM403C automatic blood pressure device and to study whether this 
accuracy was affected by subject-related factors such as blood pressure 
level, age, sex, arm circumference and pulse rate. 
Patients and methods 
The design of our study adhered as much as possible to the 1990 version 
of the protocol for validation of automatic blood pressure devices of the 
British Hypertension Society (BHS). The protocol of the American Asso-
ciation for the Advancement of Medical Instrumentation served as an 
additional guideline. We have made some adaptations and neither of the 
published protocols was followed in full. 
Terminology 
Terminology such as accuracy, reproducibility, agreement, validity and 
bias can be quite confusing. We defined accuracy as the broadest and 
most general term. Reproducibility was defined as the extent to which a 
device provides equal measurement recordings under equal conditions. 
Agreement is the extent to which measurements with one device agree 
with another device. Validity and bias are terms that we avoided because 
they refer to an absolute gold standard, whereas in blood pressure mea-
surement only a relative gold standard with its own inaccuracies is avail-
able. 
Description of the meters 
The Olmon HEM403C is a fully automatic oscillometric blood pressure 
device. It is the basic model of a series of models; other models are pro-
vided with extra facilities such as automatic inflation and a printer unit. 
The deflation rate of the cuff pressure is approXimately 3 mmHg per sec-
ond. The Hawksley random zero meter is a mercury column sphygmoma-
nometer with a technical facility that enables a variable zero position of 
the mercury column. 'The zero position can only be determined after the 
measurement and must be subtracted from the observed SBP and DBP. 
This 'blinding for expected values' during the measurement limits obser-
vation bias. 
Blood pressure IneaSlll'elnent 
Accurate auscultatory measurements are possible at a deflation rate of 3 
mmHgper second. This enabled us to choose the method of simultaneous 
single arm measurements, which is more precise than the method of se-
quentialmeasurements. The cuff of the Omron HEM403C was used dur-
ing all measurements. Its air tubing was tapped with a T-connector to the 
Hawksley random zero meter. The SBP of the random zero meter was 
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taken at the appearance of the first Korotkoff sound and the diastolic pres-
sure at the fifth Korotkoff phase (absence of sounds). The automatic me-
ter's display was blinded until the mercury measurement was completed. 
Observers 
Two ofthe three observers were experienced general practitioners and the 
third observer was a junior doctor with extensive experience in measur-
ing blood pressure. All three observers underwent an audlographic test 
and no hearing deficit was observed. They refreshed their theoretical 
knowledge about blood pressure measuring by shldyingthe 'Recommen-
dations on blood pressure measuring' as published by Petrie et al. 3 Their 
inter-observer variation was assessed by simultaneously measuring blood 
pressure ro times in each of five subjects. One cuff, which was fitted 
around a subject's arm, was connected to 3 mercury meters and one 
multi-aural stethoscope was used. One of the observers who successfully 
interpreted 95% of the test-sequence of the blood pressures of the British 
Hypertension Society video tape4 was considered the expert -observer. The 
expert-observer placed the head of the stethoscope over the brachial ar-
tery, inflated the arm-cuff to about 30 mmHg above the SBP and deflated 
the cuff at a rate of approximately 3 mmHg per second or per heart beat. 
More than 90% of the measurements between the expert-observer and 
each of the other observers and more than 85% of the measurements 
between these two observers were less than 5 mmHg apart.s 
Test-phases and Shldy subjects 
Calibratioll oft/lree OlllrOIl HEM403C devices was accomplished by fitting 
the air cuff around a solid round object and connecting it by means of a 
T-connector to a new mercury meter. Pressure readings of both meters 
were compared throughout the 300 - 20 mmHg range. At least 20 mea-
surements were performed for the individual instruments. This calibra-
tion procedure was repeated after three months. 
Tile assessmellt of agreemellt WitTl tile mercllry spllygmoma/lOmeter was per-
formed in a population of 225 subjects. They were recruited at three dif-
ferent locations. One hundred four patients were asked to cooperate after 
a regular medical consultation in general practice, 98 blood donors were 
asked during their yearly routine physical examination and 23 colleagues 
from the university department of general practice volunteered. No at-
tempt was made to recruit subjects of any particular age range or blood 
pressure level and no attempt was made to include patients with or with-
out antihypertensive therapy. Every subject's blood pressure was mea-
sured two times. Thirteen subjects were excluded from the analysis be-
cause of an irregular pulse and in 23 patients the second of the two con-
secutive measurements was not performed. Arm circumference was mea-
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sured with a measuring tape midway on the upper arm. Pulse rate and 
regularity were assessed by palpation of the pulse durIng 30 seconds. 
Tile estimation of tile reprodllcibility of tile device was based on data from the 
same study population. The variability of the differences between the 
consecutive duplicate measurements in every subject was used to com-
pare the reproducibility of the test device and the reference device. 
Data analysis 
Calibration was considered accurate when 95% of the readings of the test 
device were within 3 mmHg or 2%, whichever greatest, of the readings of 
the lnercury meter,5,6 
To assess the agreement between the Omron and the random zero meter, 
the proportions of the Om ron HEM403C measurements that differed 
from the mercury meter measurements by,; 5, ro and IS mmHg were cal-
culated and tabulated. Duplicate readings were not pooled but analyzed 
separately. Subsequently the device was graded according to the criteria 
of the British· Hypertension Society (Table 5.1). The mean and the stan-
dard deviation of the differences between the test device and the mercury 
standard were calculated to classify the device according to the criteria of 
the American Association of Advancement of Medical Instrumentation 
(AAMI). To pass these criteria, the difference between the test device and 
the standard must be'; 5 mmHg and the standard deviation of the differ-
ence ,; 8 mmHg. 
Table 5.1 
British hypertension society grading criteria for simultaneous measure-
ments5 
Difference between standard and test device 
Grade S5mmHg SlOmmHg SISmmHg 
(%) (%) (%) 
A 80 90 95 
B 65 85 95 
C 45 75 90 
D <45 <75 <90 
The blood pressure device is graded according to the proportion of the readings that are 
within 5/ 10 or 15 mmHg of theconcomitant readings with the standard measurement pro-
cedure. To reach a particular grade, all three proportions should exceed the tabulated values 
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The variability between duplicate measurements, adjusted for the physio-
logical fall in blood pressure at the second measurement was used to esti-
mate reproducibility. This estimate was calculated as the absolute value 
of the difference between the two duplicate measurements after subtract-
ing the mean blood pressure fall from this difference. The logarithm of 
this absolute value was compared between the two devices by using the 
Wilcoxon testformatched pairs. Thevariance of duplicate measurements 
can be estimated as the sum over all patients of the squared differences 
adjusted for the mean blood pressure fall, divided by twice the number 
of patients. The standard deviation of duplicate measurements is the 
square root of this variance. A multiple linear regression analysis was 
performed to assess whether a patient's blood pressure level, age, sex, arm 
circumference and pulse rate were independently related to the systolic 
and diastolic blood pressure differences between the meters. 
Results 
A summary of the characteristics of the 212 subjects in the agreement 
study is shown in Table 5.2. 
Table 5.2 
Characteristics of the subjects studied (n ~ 212) 
Women(%) 
Age (years) 
Arm circumference (em) 
Pulse rate (beats/min) 
SBP (mmHg)(%) 
SBP < 100 
100 dBP<140 
140 s SBP< 1BO 
180 s SBP< 220 
SBP > 220 
DBP (mmHg)(%) 
DBP < 60 
60 s DBP <80 
80,DBP<100 
100 s DBP< 120 
DBP > 120 
mean (sd, range) 
or proportion 
54 
48 (17, 16-88) 
28 (2, 23-37) 
74 (14,47-117) 
136 (23,86-191) 
3 
54 
39 
4 
0 
81 (14,49-119) 
3 
44 
44 
10 
0 
n: number of patients, sd: standard deviation, SBP: systolic blood pressure, OBP: diastolic 
blood pressure 
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All three tested Om ron HEM403C instruments passed the calibration 
criteria at the start of the Shldy and after three months. 
Figure s.ra and Figure s.rb 
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Differences between the systolic blood pressure (Figure 5.1 a) and diastolic blood pressure 
measurements(Figure 5.1 b) of the Om ron HEM403C and the random zero meter. Everydot 
represents the difference in one pair of simultaneous readings. Duplicate readings are not 
pooled but plotted separately. Dotted lines are drawn at the levels of a difference of 5, 10 
and 15 mmHg between the two meters. Crude regression lines are plotted in the Figures. 
SBP=systolic blood pressurel DBP=diastolic blood pressure, RZ:::random zero 
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A total of 413 systolic and 414 diastolic measurements in the 212 subjects 
were available for the agreement analysis. In Figure5.I, the blood pressure 
differences between the Omron HEM403C and the random zero meter are 
plotted by blood pressure level. SystOlic and diastolic readings with the 
Omron HEM403C were on average r mmHg (sd 9, 95% CI 0.3-2.0) and 4 
mmHg (sd 8, 95% CI 3.7-5.2), respectively, higher than those with the 
random zero meter. The quantification of the level of agreement (Table 
5.3) shows that the Omron HEM403C was graded C for both SBP and DBP 
according to the BHS grading system. The Omron HEM403C marginally 
failed the AAMI criteria for SBP and passed these criteria for DBP. 
Table 5.3 
Omron HEM403C blood pressure device compared with the Hawksley 
random zero Ineter 
Readings(%) Grading 
Device n Mean Difference 95% 
±,d ±,d C/ SS S 10 SIS BHS MM/ 
mmHg mmHg mmHg 
SSP 
403C 212 137 ± 23 
1±9 0.4-2.2 53 SO 92 C Fail 
RZ 136± 25 
DSP 
403C 212 84 ± 15 
4±8 3.6-5.1 55 85 94 C Pass 
RZ 84 ± 15 
n: number of patients, sd: standard deviation, CI: confidence interval, BHS: British Hyperten-
sion Society, AAMI: Association for the Advancement of Medical Instrumentation, SPB: 
systolic blood pressure, DBP: diastolic blood pressure, 403C: Omron HEM403C, RZ: 
Hawksley random zero meter 
The mean systolic difference between the Omron HEM403C and the ran-
dom zero meter was related to the SBP level (p<o.oor). The crude regres-
sion equation for the difference in SBP between the Omron and the ran-
dom zero meter was: y = 13.7 - 0.09(SBP) mmHg and is plotted against the 
mean SBP level in Figure 5.l. The Om ron HEM403C overestimated the SBP 
at SBP levels under 152 mmHg and underestimated the SBP at higher SBP 
levels. Multivariate linear regression analysis showed that the SBP level 
and not age, sex, arm circumference and pulse rate was independently 
related to the systolic difference between the two meters (Table 5.4). The 
mean diastolic difference between the two meters was not associated with 
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the level of the DBP. The crude regression equation, which is plotted 
against the mean DBP level in l'igure 5.r, was: y ~ L8 + 0.03(DBP) mmHg. 
The Omron HEM403C overestimated the DBP at all DBP levels. MultI-
variate linear regression analysis demonstrated that DBP level, age, sex, 
arm circumference and pulse rate were not related to the diastolic differ-
ence between the two meters (Table 5.4) 
Table 5.4 
Multiple linear regression anaiysis of the influence of blood pressure 
level, arm circumference, age, sex and pulse rate on the blood pressure 
difference between the Omron HEM403C and the random zero meter 
(n~212) 
Variable SBP difference OBP difference 
Coefficient s.e, P value Coefficient s.e. P value 
SBP level (mmHg) -0.102 0.022 0.0000 
DBP level (mmHg) 0.005 0.030 0.9 
Arm circumference (em) 0.173 0.181 0.3 0.257 0.155 0.1 
Age (years) 0.008 0.029 0.9 0.026 0.022 0.2 
Sex (men"" 0, women;=:1) -0.831 1.035 0.4 --0.991 0.907 0.3 
Pulse rate (beats/min) 0.018 0.033 0.6 -0.005 0.029 0.9 
Constant term 9.318 -3.704 
S8P difference: systolic blood pressure difference between Omron HEM403C and random zero 
meter, DBP = Diastolic blood pressure difference between Omron HEM403C and random zero 
meter, s.e.: standard error, S8P level: mean systolic blood pressure of both the meters, DBP level: 
mean diastolic blood pressure of both the meters 
The standard deviations of the systolic differences between the first and 
second measurement in the 202 subjects were 9.8 and rL5 mmHg for the 
Omron HEM403C and the random zero meter, respectively. The standard 
deviations of the diastolic differences were 7.6 and 8.5 mmHg, respec-
tively. These differences were statistically significant, which means that 
the reproducibility of the Omron HEM403C was better than that of the 
random zero meter. 
Discussion 
Assessment of the accuracy of blood pressure measurement devices is a 
rather complicated and time consuming activity. However, in view of the 
potential implications of a diagnosis of high blood pressure, it is clear 
that no device should be used without being adequately tested. Two dif-
ferent protocols exist that provide comprehensive guidelines for the com-
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plete procedure of accuracy testing. Tile Natiollal Stalldard for Electrollic or 
Automated Spllygmomallometers was published in 1987 by the American 
Association for the Advancement of Medical Instrumentation and the 
protocol from the British Hypertension Society was published threeyears 
later.,,6 Updates of both the British and the American protocol appeared 
in 1993 but were not available at the time of data collection of the present 
study. 7,8 The best way to allow comparison between test reports of differ-
ent devices is by adhering closely to these protocols. 
In our study among 212 subjects, the Omron HEM403C measured the SBP 
on average I mmHg and the DBP 4 mmHg higher than the random zero 
mercury meter. The reproducibility of the Omron HEM403C was better 
than that of the random zero meter. The agreement between both meters 
was marginally acceptable, according to the requirements of the BHS and 
the AAMI. 
Several limitations of our study should be mentioned. We have chosen 
the Hawksley random zero meter as the reference meter because it has 
been recognized for many years as the standard for 'bias free' sphygmo-
manometric blood pressure measuring. It has been used in numerous 
epidemiological studies. In accuracy studies, other investiga tors generally 
used standard sphygmomanometers instead of a random zero meter. It 
has been reported that the random zero meter systematically underesti-
mates SBP as well as DBP by 4 and 7 mmHg, respectively, and produces 
less reproducible results compared with the standard mercury manome-
ters! If one would adjusted our results for those random zero meter inac-
curacies, the overestimations of the Omron HEM403C that we have 
found would be reversed to underestimations of 3 mmHg for both SBP 
and DBP. Furthermore, one should recognize that the individual varia-
tion of the level of agreement in this study is negatively influenced by 
the lower reproducibility of the random zero meter in compared with a 
standard mercury meter. If these factors are taken into account, this 
would lead to a better classification of the Omron HEM403C blood pres-
sure device in both the British and American classification systems. The 
subject selection in this study did not completely satisfy the distribution 
of ages and blood pressures requested by the BHS or AAMI protocol; espe-
cially, patients with a SBP over 200 mmHg were not available in our pop-
ulation. This leads to a restriction of our conclusions to patients with a 
SBP < 200 mmHg. 
In every blood pressure measurement configuration for accuracy testing 
purposes, with meters connected to one cuff, the T-connected air tubes 
of the oscillometric device and the random zero manometer hold a larger 
air volume than the automatic oscillometer in a stand-alone situation. To 
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exclude the possibility that the larger air volume affects the accuracy of 
the oscillometric device we performed ten measurements in one subject 
with the experimental measurement configuration on one arm and a 
stand-alone oscillometric device on the other ann. Blood pressure was 
measured simultaneously on both arms of the subject with an adjust-
ment for left to right arm blood pressure difference. We found no influ-
ence of the slightly enhanced volume of the air tubes in the measure-
ment configuration that we used on the measurement accuracy of the 
Omron HEM403c' 
The influence of blood pressure level on the accuracy of the measure-
ments has been reported earlier.'" This phenomenon can only be ex-
plained by a deficiency in the software protocol of the oscillometric de-
vice. In principle, the software protocols that are used in oscillometric 
devices should be able to adjust for this kind of systematic inaccuracy 
that is linearly dependent of the blood pressure level. Our results show a 
mean underestimation of the SBP of 1 mmHg at a SBP level of 160 mmHg 
and a mean overestimation of 5 mmHg at a DBP level of 95 mmHg. These 
blood pressure levels are crucial for the decision about the treatment of 
patients. In view of that the systolic inaccuracy that we found is accept-
able, but the diastolic inaccuracy is quite large. 
To our knowledge, only one earlier accuracy study of the Omron 
HEM403C was published. U This study showed a mean systolic underesti-
mation of 5 (sd 9) mmHg and a correct diastolic estimation (sd 5) of the 
OImon HEM403C compared with a standard mercury manometer; the 
device was classified as B/C according to the BHS grading criteria and it 
fulfilled the AAMI criteria for DBP and failed these criteria for SBP. This 
earlier study, however, may be criticized because of its small number of 
subjects (n=17) and the methods applied to assess agreement. 
Only few oscillometric blood pressure meters receive' A or B' grades in the 
BHS classification system. In comparison to other recently tested auto-
matic blood pressure devices the Omron HEM403C is reasonably accu-
rate." One should keep in mind that we used a random zero meter as the 
reference meter, which certainly caused some overestimation of the inac-
curacy of the Omron HEM403c' 
The general performance of the device was good; its construction was 
solid and working with it was practically without hindrances. The pa-
tients did not encounter much discomfort during the measurements. The 
number of invalid readings by external disturbing factors was small and 
no technical failures occurred during the test period. 
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The technicians of the manufacturing companies potentially may change 
the software protocols of electronic devices at any moment during the 
production. For this reason it is necessary to assess the accuracy of every 
new series of electronic devices that is produced. Even then one cannot 
completely trust the uniformity of the cut-off points within one series of 
a meter of the same type. These uncertainties are a consequence of the 
'black box' character of automatic devices and must be considered a dis-
advantage of automatic devices that does not apply to mercury manome-
ters. Mercury meters do not have factory-set, software determined, cut-off 
points. 
In the cases that patients use automatic devices for self-measurements at 
home, we agree with the remark ofJames et ai, that it would be preferable 
to test the agreement of a blood pressure device every time It is fitted to 
a particular patient.'3 This can easily be done by performing some, for 
example 10, blood pressure measurements with the automatic device and 
a reference mercury meter, both connected to one cuff that is fitted 
around the arm of the patient. The device should at least achieve C 
grades in the BHS grading system. This implies that >45% of the measured 
differences should not outreach 5 mmHg, >75% should not outreach 10 
mmHg and >90% should not outreach 15 mmHg. The result of such a 
mini test is of course only applicable to the particular patient-meter com-
bination that was tested, and the results hold only at blood pressure lev-
els that approximate the level during the mini-test. The requirements for 
such a mini test are 10 em of air tube, a T- or Y-connector and ro min of 
time investment of the doctor. 
We conclude that the Omron HEM403C is accurate enough to be recom-
mended for those clinical and research purposes that require automatic 
measurements. 
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Validation of blood pressure measuring devices 
After publication of our results on the accuracy of the automatic 
oscillometric blood pressure measuring device Omron HEM403C in the 
Journal of Human Hypertension, the authors of the British Hypertension 
Society (BHS) Protocol for the evaluation of blood pressure measuring 
devices, O'Brien and Atkins, wrote a critical letter to the editor. This letter 
was published, together with a comment of our group in one of the later 
issues of the Journal of Human Hypertension. The letter of O'Brien and 
Atkins and our reply are reproduced in full underneath. 
Accuracy of an oscillometric automatic blood pressure device: the 
Omron HEM403C (letter of O'Brien et al. J Hum Hypertens 1995;9: 
781-2) 
Walma and colleagues, having performed a validation study on the 
Omron HEM403C, conclude: 'According to the criteria of the British Hy-
pertension Society (BHS) the Omron HEM403C is accurate enough to be 
recommended for those clinical and research purposes that are in need 
of automatic measurements'.' This conclusion is invalid for a number of 
reasons, foremost among which is the fact that, contrary to what the 
au thors state, the OmronHEM403C does not achieve the acceptable levels 
of accuracy now recommended in the revised BHS protocol,' nor does it 
fulfil the criteria for accuracy of the Association for the Advancement of 
Medical Instrumentation (AAMI).'" However, if the results were valid, 
critical discussion would only need to focus on the topic of what consti-
tutes an acceptable level of accuracy in clinical practice, but these results 
are not valid because the study did not adhere to the requirements of the 
first BHS protocol, S which the authors claim to have followed, and this 
raises other important issues. 
Firstly, the failure to comply with the protocol requirements merits con-
sideration: the BHS protocol stipulates that 85 subjects must be recruited 
carefully to provide clearly defined levels of blood pressure (BP) that will 
test the device across the pressure range seen in clinical practice.s In the 
Walma study, subjects were recruited from a population that could not 
have yielded the BP range demanded by the protocol; and most BPs were 
in the range ro5160 to 150/95 mm Hg, namely the normotensive range. 
Serious though this may be, the main protocol violation was substitution 
of the Hawksley random zero sphygmomanometer recommended in all 
protocols.'·s This was done with the laudable intention of reducing ob-
server bias but the Hawksley, as the authors acknowledge, has been 
shown to underestimate BP' and the effects this may have on validation 
studies has been discussed in detail by us.' In a further study we com-
bined a database of paired BP measurements using the Hawksley random 
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zero sphygmomanometer and a standard mercury sphygmomanometer 
and a database of paired measurements made on a SpaceLa bs 90202 ambu-
latory recorder to determine how the SpaceLabs 90202 would have been 
fared if it had been assessed against the Hawksley sphygmomanometer 
instead of a standard sphygmomanometer. The effect of replacing the 
standard ins trumentwith a Hawksley sphygmomanometer was to reverse 
the direction of the average measurement error found and to demote the 
SpaceLabs 90202 from BHS grades C and B, for systolic and diastolic accu-
racy, respectively, to grade D - overall the lowest rating of accuracy in the 
BHS grading system.' Therefore, the conclusions of validation studies 
using the Hawksieysphygmomanometer as to the accuracy or inaccuracy 
of the device being validated must be regarded at very least as being ques-
tionable. Moreover, it is quite unacceptable to apply an correction factor, 
as the authors do, because the error in the Hawksley is not systematic. 
However untenable all this may be in terms of adhering to protocol re-
quirements, the authors then compound their disregard for procedure by 
publishing their erroneously derived results as satisfying protocol require-
ments and therefore permitting the recommendation that the device is 
acceptable for clinical use. The Om ron HEM403C achieved a CjC grading 
according to the BHS protocol and failed the AAMI criteria of accuracy for 
systolic pressure while barely satisfying the accuracy criteria for diastolic 
pressure which should lead to the recommendation that the device not 
be used in clinical practice. 
This is not, however, the end of the debacle. The Omron HEM403C may 
well be an accurate device and experience with another closely related 
model would suggest that this might well be so if the algorithms in the 
two models are similar! But, on the basis of this study, no statement as 
to the accuracy or inaccuracy of the Omron HEM403C is possible. 
Finally, a concluding statement may be devoted to expressing a degree of 
scientific disquiet. The BritishHypertension Society has taken the trouble 
to constitute a Working Party which published a protocol for validation 
of BP measuring devices in I9905 which was revised in I993.' The Associa-
tion for the Advancement of Medical Instrumentation likewise published 
its protocol in I9863 and this was revised in I993.4 That it has been neces-
sary to write six letters in the past year to alert researchers and potential 
purchasers of BP measuring devices that papers published in peer re-
viewed journals by failing to comply with protocol requirements were, 
therefore, questionable or invalid, is a cause for concern, particularly as 
such letters inevitably fail to influence the statement of the original pa-
per. IOOIS 
E O'Brien, N Atkins 
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Accuracy of an oscillometric automatic blood pressure device: the 
Omron HEM403C (reply of Walma et aI. J H Hum Hypertens 1995;9: 
781-2) 
We thank Drs O'Brien and Atkins, both recognized authorities in the field 
of validatlon of blood pressure devices, for taking the trouble of criticiz-
ing our publication: 'Accuracy of an oscillometric automatic blood pres-
sure device: the DImon HEM403C'. 
Our conclusion that the Omron HEM 403C is accurate enough to be rec-
ommended for those clinical and research purposes that are in need of 
automatic measurements does not meet wi th the approval of O'Brien and 
Atkins. Their arguments, however, are not veIY convincing. 
In our eyes, it is not correct to apply the grading criteria of the 1993 ver-
sion of the protocol of the British Hypertension Society (BHS) to a study 
conducted according to the 1990 version of the BHS protocol, as O'Brien 
and Atkins suggest. Procedures and grading criteria were significantly 
altered, for example the method of simultaneous same-arm measure-
ments was abandoned. Importantly, the revised 1993 protocol came avail-
able after the completion of our data collection and the 1990 protocol 
does not provide clinical inferences of the A,B,C and D grading system. 
Until recently, devices with A grades did not exist at all, B grades were 
rare and D grades were very frequently encountered in validation studies 
of automatic blood pressure devices. Our conclusion that a C graded de-
vice was acceptable seems adequate. The Omron HEM403C satisfied the 
criteria of the American Association for the Advancement of Medical 
Instrumentation (AAMI) for diastolic blood pressure (DBP) values and 
marginally failed to satisfy these criteria for systolic blood pressure (SBP). 
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If we would have used a standard mercury sphygmomanometer instead 
of the Hawksley random zero meter, as advised in the AAMI protocol, the 
Omron HEM403C would certainly have satisfied the AAMI criteria for 
SBp, as we will explain. 
The subject selection in our study did not completely satisfy the distribu-
tion of BP levels as requested by the BHS protocol. Patients with SBP levels 
> 180 mmHg and DBPs > roo mmHg were not sufficiently available in our 
population. To enable assessment of the accuracy of the device at these 
high BP levels we explicitly presented the relation between BP level and 
the accuracy of the Omron device. The substantially larger number of 
patients in our study than requested in the BHS protocol made this feasi-
ble. Crude regression lines were drawn in Bland and Altman plots and the 
results of a multiple linearregression analysis were presented in a separate 
Table. Indeed, the Inaccuracy of the SBP of the test device increased at 
very low and very high BP levels. Consequently, we clearly mentioned in 
the discussion paragraph that our conclusions about the validity of the 
test device are restricted to patients with a SBP < 200 mmHg. 
Another point of criticism was the use of the Hawksley random zero me-
ter (RZ meter) as the reference device in our study. The BHS protocols 
prescribe the use of a standard mercury sphygmomanometer. The RZ 
meter is technically nothing else than an open mercury manometer and 
therefore, if properly used, it should produce results identical to any stan-
dard mercury manometer. The randomly variable zero point of the RZ 
meter has to be recorded immediately after each BP measurement by the 
observer and too rapid recording of the zero pOint level can introduce 
bias because of the slow return of the mercury column to the zero point. 
Also some expectation bias may still exist at those readings that were 
highly elevated by the zero-muddler. These two biases work in the same 
direction.'·3.4 The use of standard sphygmomanometers, however, in-
duces more expectation bias and terminal digit preference. Duplicate and 
triplicate measurements, as dictated in the 1990 BHS protocol, are most 
susceptible for expectation bias. This artificially diminishes the variance 
of the differences between the test device and the reference device. On 
the other hand, the variance of the RZ measurements Is increased as RZ 
measurements are the result of two measurements, namely the BP value 
and the zero point value. All this explains why the Omron HEM403C 
would certainly have satisfied the AAMI criteria if a standard mercury 
sphygmomanometer would have been used. 
The O'Brien group published data on the magnitude of the differences 
between RZ meters and standard sphygmomanometerss,6 and we have 
taken these data into account in the inference of the C grade of the 
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Omron HEM403C to the acceptability for clinical practice and research 
purposes. In contrast to the statement of O'Brien and Atkins we did not 
use a correction factor to adjust for these differences. 
Finally, a conduding statement maybe devoted to the exceptional com-
plexity of the BHS protocols and the unrestrained criticism of O'Brien 
and Atkins, both members of the Working Party on Blood Pressure Mea-
surements of the British Hypertension Society, on investigators who per-
mit themselves some deviations from the BHS protocols. The simple fact 
that O'Brien et al. felt obliged to write six letters to various peer reviewed 
journals in the past year about protocol deviations illustrates the difficul-
ties in adhering precisely to the BHS protocols. We do underwrite the 
usefulness of uniform and carefully designed validation procedures for 
BP devices, but extreme complexity of protocols, rapid revision and ven-
omous criticism by the members of the working party of researchers devi-
ating from the protocol, discourages other groups to follow these proto-
cols. Until now, the majority of validation studies of BP devices came 
from the Dublin laboratory, but from a scientific point of view it is desir-
able that this work can be reproduced by other iaboratories. It is inevita-
ble that protocolized validation studies of BP devices are more or less 
cooking-book exercises, but some deviations and the addition of supple-
mentary flavours by researchers should be tolerated. 
EP Walma, C van Dooren, AW Hoes 
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6 Withdrawing long-term diuretic therapy in the elderly: a study in general practice in 
the Netherlands. 
Introduction 
Polypharmacy and long-term drug use increase with age, as do the num-
ber of adverse reactions due to side effects and pharmacological interac-
tions. '.'.M.5.6 Diuretics rank high on lists of most prescribed drugs for the 
elderly and are frequently responsible for adverse side effects. 7.8,9 • .0 Recent 
surveys demonstrated that approximately 20% of the elderly population 
uses diuretics. II,I2,13 
The most common indications for prescribing diuretics are hypertension, 
congestive heart failure, and orthostatic ankle edema caused by insuffi-
ciency of the venous system of the legs.'4 Edema caused by renal or he-
patic diseases, hypercalciuria, and glaucoma are infrequent indications 
for diuretic therapy. 
Hospital based studies have shown that, under certain circumstances, 
diuretics can be stopped successfully. '5.·6.'7,.8.'9.00 In these studies the pro-
portion of patients that were successfully withdrawn from diuretic ther-
apy ranged from 7I% to 89%. There are few similar studies in outpatient 
general practice settings." Patients in hospital geriatric wards or nursing 
homes have special characteristics, and conclusions drawn from research 
on these patients do not necessarily apply to the elderly diuretic-user in 
general practice. Further, the monitoring possibilities during drug with-
drawal are less optimal in general practice than in the hospital, where 
more clinical tests to monitor the condition of the patient are readily 
available. Therefore, other inclusion and monitoring procedures are 
needed in the general practice setting to limit the risk of developing heart 
failure or severe hypertension after withdrawal of the diuretic. To protect 
patient safety, we designed inclusion/exclusion criteria and monitoring 
procedures applicable to general practice. 
We conducted a general practice study to assess what proportion of long-
term diuretic-users could discontinue their diuretic therapy without ne-
gative clinical consequences. Also evaluated were the influence of diu-
retic withdrawal on blood pressure, heart failure score, peripheral edema, 
body weight and subjective complaints of the patient. The study reported 
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here is a pilot study for a large multi centered randomized controlled trial 
of diuretic withdrawal in general practice. 
Methods 
Subjects for this pilot study were drawn from one general practice of ap-
proximately 2,000 patients in Schoonhoven, a small town (population 
II,OOO) located 20 miles east of Rotterdam in The Netherlands. We re-
viewed the medical records of all patients in the practice who were aged 
65 or older (N~280) to identify those who were currently using diuretics, 
and had been using them for six months or longer. We identified 52 such 
patients, and then excluded those who met one or more of the following 
criteria. 
First, we excluded patients who had hypertension for less than one year, 
even if it was treated and well-controlled. Second, we excluded those 
with unsatisfactorily regulated hypertension, defined as more than one 
measurement over I65/95 mmHg, either recorded in the medical file dur-
ing the last year, or as determined at baseline measurements for this 
study. The mean of two consecutive blood pressure recordings was taken 
at baseline and all follow-up visits. Blood pressure was measured in sitting 
position using an automated digital device, type: Yamasu YSE 320, which 
had been shown to be reliable and accurate." Korotkoff V sounds deter-
mined the diastolic cut-off level. Third, we excluded patients who had a 
documented medical history of one or more episodes of acute left-sided 
congestive heart failure, occurring at any time in the past, or any symp-
toms of congestive heart failure occurring within the preceding three 
months. To identify patients with a history or symptoms of heart failure, 
all files were examined thoroughly by two general practitioners. Symp-
toms of heart failure were defined as increasing dyspnea or ankle edema. 
Fourth, we excluded patients with heart failure scores over three points 
(Table 6.I). We used a heart failure score list based on anamnesis and 
physical examination, adapted from a scoring system reported by 
Gheorghiade et al.'J 
Fifth, we excluded patients with edema caused by renal or hepatic dis-
ease, hypercalciuria or glaucoma. Finally, we excluded patients who, ac-
cording to the general practitioner, were unable to adequately answer 
simple questions about his/her health status. 
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Table 6.1 
Heart failure score 
- Paroxysmal nocturnal dyspnea (in preceding three months) 
- Dyspnea on exertion (in preceding three months) 
- Elevated jugular venous pressure (>R-4) 
- Tachycardia (> 100/min) 
- Hepatojugular reflux 
-lower pulmonary crepitations 
- S3 galop-rhythm 
- Two-sided pitting edema of the legs 
- Hepatomegaly 
The heart failure score varies from 0-13 points. 
points 
3 
2 
2 
1 
1 
1 
1 
This heart failure score is a modification from a similar list developed by 
Gheorghiade and Beller.23 It was developed as a quantification of the clinical 
symptoms and signs of congestive heart failure that could be obtained at home 
with the patient. The weights of the items are based on clinical judgement 
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Basically, these exclusions were chosen to avoid withdrawing diuretics 
from patients who had clear indications for diuretic treatment and to 
thereby reduce the risk of inducing acute left-sided heart failure upon 
diuretic withdrawal. 
The protocol of the study was approved by the medical ethics committee 
of the Academic Hospital Dijkzigt in Rotterdam. The patients were visited 
at home by their family doctor to explain the purposes and the proce-
dures of the study and to ask for their willingness to cooperate. All but 
one patient cooperated and signed written informed consents. 
Dillretic witlldrawal 
Diuretics were withdrawn according to the following schedule. Thiazides 
and furosemide in daily dosages of <40 mgs were stopped at once, while 
daily dosages of 40 mgs of furosemide were halved during one week 
before complete withdrawal. All patients were visited eight times at 
home by their family physician: one week and one day before with-
drawal, and two days, one week, two weeks, one month, three months, 
and six months after withdrawal of diuretics. Heart failure scores were 
recorded and blood pressures were measured as described above. Body 
weight was measured with a digital balance (Tefal type, on which cali-
bration was performed every three months to a variability of less than 
lOa grams). Ankle edema was quantified by measuring the ankle circum-
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ference with a measuring tape just above the malleoli at the slimmest 
point. The reproducibility of this method was determined by measure-
ments (N=93) at the same ankle of the same person at three different 
days. A standard deviation of 0.07 cm with a mean circumference of 2L5 
cm was found. 
During the six-month follow-up period, diuretics were resumed if the 
subject developed: 
(a) Heart failure score >4, (b) Systolic blood pressure >180 mmHg and/or 
diastolic blood pressure >95 mmHg at more than one occasion, or (c) 
Upon request of the subject. 
The Shldent-t test for paired observations and the Wilcoxon rank-sign 
test were used to evaluate the clinical consequences of withdrawing di-
uretic therapy. 
Results 
Of all 280 patients of 65 years or older in this one general practice, 20% of 
the women and 16% of the men had been using diuretics for six months 
or longer, for a total of 52 subjects (19%). The prevalence of diuretic ther-
apy increased with age from 17% in women aged 65-69 to 46% in women 
of 85 years or older. The corresponding percentages in men were 3% and 
73%, respectively. The median duration of diuretic use was two years and 
three months. Ten percent of the patients had been on diuretic therapy 
for a period of IO years or longer. 
Initial indications for diuretic therapy in the subjects who participated in 
this study were congestive heart failure (17), hypertension (21), ankle 
edema (six), and hypercalciuria (one). In 13 patients no indication could 
be found. The prescribing physician was the general practitioner in 35 
cases and a specialist in 16 cases; in one case the prescribing physician 
could not be determined. 
Of the 52 patients on long-term diuretic therapy, II patients died before 
the actual withdrawal of their diuretics; in three patients, the diuretic had 
already been withdrawn. We excluded 22 patients from the remaining 
group of 38 users because of hypertension in the preceding year (12), 
symptoms of overt congestive heart failure in the preceding 3 months 
(five), mental deterioration (four), and hypercalciuria (one). In addition, 
one patient refused to participate in the study. 
Table 6.2 
Effect of withdrawal of diuretics in 15 patients aged 6S and older in general practice 
_ .. -
# M/F Age Diu Dose Stact Dura· R,- Reason Before withdrawal" After withdrawalS 
retic (mgs indica- tion of sumed to re-
per day) tion use after sume HF- Body SBP DBP ankle HF- Body SBP DBP ankle 
(m) score weight (mmHg) (mmHg) circum score weight (mmHg) (mmHg) circum 
(mm) (mm) 
Successful withdrawn from diuretic treatment 
1 F 74 fu 40 unknown 30 2 66 115 67 279 4 67 133 71 285 
2 M 89 et 4/50 HF 23 2 54 131 80 191 0 55 123 68 194 
3 F 89 fu 40 HF 67 0 46 134 61 210 0 47 142 62 217 
4 F 87 fu 40 HF 87 3 86 143 65 240 2 87 145 66 245 
5 M 67 et 4/50 HT 94 0 69 159 81 217 2 70 133 78 223 
6 F 78 fu/tri 20/50 HF >168 1 74 129 91 264 4 76 146 88 271 
Diuretic treatment resumed within six months 
7 90 fu 20 oedema 95 5.5m HF 2 61 139 82 220 9 62 149 82 220 
8 F 67 chi 25 HT 40 2m HT 1 61 153 88 246 3 62 171 89 259 
9 M 79 fu/et 40/4/50 unknown 32 2d HT 1 62 165 63 238 3 65 202 65 240 
10 F 73 fu 40 HF/HT 21 <ld HT 3 74 167 87 208 3 74 184 90 215 
11 M 74 fu 40 HF 56 lw Asthma 2 70 178 55 213 7 70 170 40 213 
12 F 82 fu 20 HF 29 2w Oedema 3 71 166 75 239 2 74 163 71 253 
13 F 84 fu 40 HF 45 4m Oedema 2 82 148 70 235 2 85 154 81 243 
14 F 71 fu 11.4 unknown 37 2m Subj.c. 0 83 150 74 22S 2 82 157 69 227 
15 F 69 chi 2S unknown 51 2w SUbj.c. 2 81 169 69 217 3 82 174 74 220 
~ All values are the mean of!Volo duplicate measurements per patient at week-1 and day _1, S All values are the mean of all measurements after withdrawal of diuretic treatment, 
ranging from 1 duplicate measurement at day +2 in patients who resumed early, to six duplicate measurements in patients who were successfully withdrawn from diuretics. ® resumal 
uring dose reduction week 
F = Female, M = Male, fu = furosemide, et= epitizide/triamterene 4/50 mg, tri = triamterene, chi = chlortalidone, HF = heart failure, HT = hypertension, m = months, d = days, W:::: 
weeks" subj.c. = subjective complaints 
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After excluding ineligible subjects, the pilot study of diuretic withdrawai 
involved rs patients, II women and four men. The mean age was 78 
(range: 67 to 90). The mean duration of diuretic therapy in this group was 
five years and indications for treatment were: heart failure (seven), hyper-
tension (two), heart failure plus hypertension (one), ankle edema (one) 
and unknown (four). More detailed information about those patients is 
summarized in Table 6.2. 
Six months after the withdrawal of diuretic therapy six otIs patients were 
still not taking diuretics. In nine patients diuretic therapy was resumed. 
The reasons for resuming diuretic therapy were hypertension (three), 
symptoms of congestive heart failure (one), or asthma (one), subjective 
complaints of the patient (two,) and ankie edema (two). The one patient 
in whom congestive heart failure developed experienced the problem 
following surgical therapy of a hip fracture that occurred five and a half 
months after withdrawal of the diuretics. One patient developed a severe, 
persistent episode of bronchial asthma. The sudden occurrence of bron-
chial asthma in this patient after the withdrawal of diuretics prompted 
us to resume diuretic therapy and even to double the dose. On recur-
rence, this bronchial asthma was only manageable by adding high doses 
of sodium cromoglycate to the already extensive pulmonary medication 
of this patient. In two cases, diuretics were restarted following the pa-
tient's request based on subjective complaints such as atypical chest pain, 
dizziness, increased fatigue, and shortness of breath during exercise. Fi-
nally, troublesome ankle edema was the reason for resuming diuretics in 
another two patients. 
Withdrawal of diuretics influenced blood pressure, heart failure scores, 
body weight, and ankle edema. Systolic blood pressure increased on aver-
age 6 mmHg (o.oS<P<O.I), but no changes in diastolic blood pressure were 
found. The heart failure score rose I,S points (O.01<P<O.Os), attributable 
to an increased prevalence of dyspnea during exercise. The withdrawal of 
diuretics caused a mean rise of body weigh t of 1.2 kgs (p<o.oor), predomi-
nantiy in the first two weeks after withdrawal. Ankle circumference in-
creased 0.6 cm (p< o.oor). 
Discussion 
In our pilot study for a randomised clinical trial in general practice, six 
out of IS patients (40%) were successfully withdrawn from their diuretic 
therapy. This proportion is lower than has been reported in the literature. 
Hospital-based studies reported that 71 to 89% of patients could be suc-
cessfully withdrawn from diuretic therapy. '6,.8.'9.>0 A recent Norwegian 
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study in general practice showed successful withdrawal in 18 of 33 elderly 
patients (55%)." The difference between our results and others may be 
explained partly by differences in inclusion and exclusion criteria and 
partly by the small sample size in our study. Differences between hos-
pital-based patient populations and a general practice population may 
account for the different results as well. Finally, the less optimal monitor-
ing conditions in the general practice setting, in comparison to hospital-
based studies might have caused us to adopt a low threshold for restarting 
diuretics. The fact that diuretics were restarted in four of 9 cases for rea-
sons other than hypertension or heart failure supports this notion. 
Eleven of our 52 patients died before we even started the withdrawal at-
tempt. 
This high death rate among diuretic-users rellected the poor prognosis of 
the very old with cardiovascular disease among our patients (mean age 
of the deceased patients was 85 years). Note also that there was a time-
delay of approximately one year between the identification of our study 
population and the actual start of the withdrawal study. 
The mean increase in systolic blood pressure following diuretic with-
drawal was 6 mmHg, which was in accordance with other reports.'6"9The 
rise in the heart failure score is partly explained by an increase in short-
ness of breath in two patients, one with congestive heart failure after 
surgery for a hip fracture and another with bronchial asthma. Because of 
the small number of patients in our pilot study, changes in heart failure 
score of even a few subjects affected the overall group's mean heart failure 
score, An increase in body weight, almost certainly caused by water and 
salt retention, occurred in our subjects, mostly in the first two weeks after 
withdrawal. This emphasizes the need for careful monitoring forconges-
live heart failure signs during the early period, following the withdrawal, 
although alertness seems warranted beyond that period, Thorough in-
struction of the patient about changes in symptoms of shortness of 
breath is mandatory. Changes in body weight reported in the literature 
are of a smaller magnitude than in our study, which could be a rellection 
of the susceptibility for heart failure of our population. '70'8,'9 A mean in-
crease of the ankle circumference of 0,6 cm is eqUivalent to an increase 
of the skin thickness of 0.1 cms. Such a slight increase may be noted by 
the patient but will generally not be perceived as troublesome. Both an 
increase and a decrease of ankle edema after withdrawal of diuretics have 
been reported by others.'6,,8,," 
A limitation of this study is the absence of a control group. Thus, changes 
after withdrawal of diuretics may also have been caused by factors other 
than the actual withdrawal of the drug. A randomized controlled trial 
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would be the method of first choice to exclude this possibility. Secondly, 
the sample size in our study was small, limiting conclusions that can be 
drawn from our data. As a result of this pilot study, however, we are cur-
rently conducting a multicenter randomized controlled trial of diuretic 
withdrawal in 200 patients in general practice. 
We conclude that long-term diuretic medication in elderly patients in 
general practice may be safely withdrawn from up to 40% of patients 
without recent symptoms of hypertension or congestive heart failure. 
However, careful medical monitoring afterdimetic withdrawal is manda-
tory. A regular evaluation by general practitioners of the need for long-
term diuretic therapy may be useful in reducing pOlypharmacy and 
ovennedication. 
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7 Withdrawal of long-term diuretic medication in elderly patients: 
a double-blind randomized trial. 
Introduction 
Diuretics are among the most frequently prescribed drugs in westernized 
societies with approximately 20% of all elderly patients using diuretics as 
long-term therapy""'''''' Approximately one third of these patients use 
diuretics because of heart failure, one third because of hypertension and 
one third because of the much weaker indication non-cardiac ankle oe-
dema.' 
Unnecessary use of diuretics should be minimized because of potentially 
serious side effects such as hypokalemia, hyponatriemia and dehydra-
tion.6",8,9 Based on results of randomized trials, several national guide-
lines for treatment of hypertension recommend attempts of dose reduc-
tion and eventually cessation of antihypertensive therapy if blood pres-
sure levels remain acceptable during one to two years of treatInent. IO,II,I2,13 
The possibility of withdrawing diuretic therapy in heart failure patients 
has never been studied in a randomized trial and recommendations 
about dose reductions or cessation of diuretic therapy are currently not 
available, 
Primary care physicians account for the majority of diuretic prescrip-
tions. '" We therefore performed a double-blind randomized trial among 
elderly patients in general practice to assess what proportion of elderly 
patients may be successfully withdrawn from diuretic therapy. 
Methods 
Patients 
Patients of 65 years or older who had been on diuretic treatment for at 
least 6 months, and were without overt heart failure or hypertension were 
eligible for the trial. By scanning the pharmacy registers of eight general 
practices a total of 470 patients receiving long-term diuretic therapy was 
identified, of whom 268 were excluded because of the following reasons: 
(r) a history of acute heart failure, defined as hospitalization or require-
ment of intravenous diuretic therapy (n=27); (2) symptoms of heart fail-
ure during the last 3 months (n=2r); (3) manifest heart failure, defined as 
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a heart failure score (see below) exceeding 4 points (n~39); (4) present use 
of furosemide dosages exceeding 80 mgs/day (n~26); (5) mean of three 
blood pressure values (two measured at successive home visits and one 
obtained from the medical file) > 180/roo mmHg (n=2I); (6) hyper-
calciuria, nephrotic syndrome and glaucoma as indication for diuretic 
therapy (n~2); (7) use of fixed combinations of diuretics with beta-block-
ers or ACE-inhibitors (n=25); (8) combination therapy of beta-blockers, 
diuretics and vasodilators for hypertension (n~2); (9) use of a diuretic for 
which no placebo was available (n=40); and (10) non-compliance during 
the run-in phase (n~I). In addition, 57 patients or their general practitio-
ners refused to cooperate and seven eligible patients could not be enroled 
in the trial because of logistic reasons. Each general practitioner filled out 
a questionnaire to assess the current indications for diuretic treatment in 
the patients included in the trial. 
Study protocol 
During the study period, participants were visited eight times at their 
homes by one of two study physicians (EPW, CvD). The run-in phase of 
4 weeks included two home visits to collect the baseline data, to monitor 
the run-in phase and to perform the randomization. At the first home 
visit all diuretic medication was handed over to the research doctor and 
replaced by active run-in medication of the corresponding diuretic. At 
the second home visit, at the end of the run-in phase, patients were ran-
domly assigned to placebo (the withdrawal group) or to continuation of 
diuretic therapy (the control group), after stratification by age (65 to 79 
and ;0,80 years) and type of diuretic. Matching placebo was available for 
the five diuretics or fixed diuretic combinations most often prescribed in 
our region: furosemide, chlorthalidone, hydrochlorothiazide/triamterene, 
epitizide/triamterene and triamterene, covering 90% of all diuretic use. 
Patients with furosemide dosages of 40 or 80 mgs daily went through a 
dose-halving regimen of I and 2 weeks, respectively, to prevent severe 
rebound effects. Dose-halving was started immediately after randomIza-
tion and was performed dOUble-blind. 
The six follow-up visits took place 2 days, I and 2 weeks and I, 3 and 6 
months after randomization. Heart failure score, body weight, ankle oe-
dema and blood pressure were assessed at baseline and at all follow-up 
visits. Heart failure symptoms were quantified by means of a standardized 
scoring list. This is a modification of the list used by Gheorghiade et aI., 
compromising symptoms and signs that may be collected at the patient's 
home.'4These included: paroxysmal nocturnal dyspnea in the preceding 
week (3 points); dyspnea on exertion in the preceding week (2 points); 
distention of the jugular vein above R -4 cm (2 points); heart rate> lOO 
beats/min (1 point); presence of hepatojugularreflux (I point); lower pul-
7 Withdrawal of 100lg-term diuretic medicatioll ill elderly patiellts 95 
monary crepitations (r point); S3 gallop-rhythm (r point); two-sided pit-
ting ankle oedema (r point) and hepatomegaly (r point). This symptom 
score list appeared a valid instrument in previous studies.5• '5 
Dyspnea on exertion was assessed at baseline and I and 6 months after 
randomization by means of a questionnaire, and by subtracting respira-
tion frequency at rest from the frequency recorded immediately after the 
patient redressed following the physical examination. Body weight was 
measured with a digital balance and calibration was performed every 3 
months. Ankle edema was quantified by measuring the smallest ankle 
circumference with a measuring tape. During the study, duplicate blood 
pressure readings were taken with an Om ron HEM403C oscillometric, 
automatic device with the patient in a sitting position." The arm with 
the highest blood pressure level was determined at the first session and 
taken throughout the shldy for further measurements. An ECG was re-
corded at baseline and one month after randomization. Blood samples 
were taken at baseline and at 6 months after randomization. Serum so-
dium, potassium, glucose, uric acid, cholesterol, HDL-cholesterol and 
creatinine levels were determined using routine procedures in the re-
gional clinical laboratory. Drug compliance was checked by counting 
tablets at every follow-up contact and by assessment of serum diuretic 
levels in blood samples at the start and the end of the Shldy. High pres-
sure liquid chromatography and UV fluorescence methods were applied 
to determine serum levels of chlorthalidone, triamterene and furosemide. 
The blinding procedure of this study was tested at r month after random-
ization by asking both the patient and the trial doctors their opinion 
about the content of the trial medication: placebo or verum. 
The protocol was approved by the Medical Ethics Committee of Erasmus 
University/Academic Hospital Dijkzigt Rotterdam, and written informed 
consent was obtained from all patients. 
Outcome variables 
The primary outcome variable of the Shldy was successful withdrawal 
from diuretic therapy. Patients who still were on blinded study medica-
tion at the end ofthe 6 months follow-up period were considered success-
fully withdrawn. Those patients who did meet one of the predefined cri-
teria for requiring diuretic therapy within the 6 months follow-up period 
were considered to be unsuccessfully withdrawn. Criteria for requiring 
diuretic therapy were: (I) heart failure score exceeding 4 points, and (2) 
mean of three duplicate systol ic or diastol ic blood pressure measurements 
at separate occasions >180 or >roo mmHg, respectively. Further, patients 
in whom diuretic therapy was reinitiated by their phYSician for other 
reasons, e.g. increase in ankle circumference or subjective symptoms, 
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were considered to be unsuccessfully withdrawn. An additional com-
bined outcome was constructed as 'any increase In heart failure score 
and/or systolic blood pressure level exceeding r60 mmHg or diastolic 
blood pressure level exceeding 90 mmHg'. 
Table 7.1 
Baseline characteristics of the participants 
Withdrawal group Control group 
Characteristic (n=102) (n=100) 
Age (years) 76± 1 76 ± 1 
Women(%) 79 70 
CUrrent indication for diuretic therapy (%) 
Heart failure 45 38 
Hypertension 41 46 
Oedema 13 15 
Other/Unknown 1 
Heart Failure score (0 to 13) 1.4 ± 0.1 1.5±0.1 
NYHA classification of all patients (%) 
1 (no limitation of physical activity) 80 77 
2 (some limitation of physical activity) 16 19 
3 (marked limitation of physical activity) 3 4 
4 (severe limitation of physical activity) 0 
Increase of respiration rate 
after redressing (#/minute) (n=62, 67) 3.4 ± 0.5 4.1 ± 0.6 
Systolic blood pressure (mmHg) 147 ± 2 147 ± 2 
Diastolic blood pressure (mmHg) 81 ± 1 81 ± 1 
80dy weight (kg) 76 ± 1.2 75 ± 1.1 
Ankle circumference (em) 22.6 ± 0.2 22.3 ±0.2 
Irregular pulse (%) 26 28 
Previous myocardial infarction (%) 11 14 
Diuretic therapy (%) 
Furosemide (including combinations 30 33 
with other diuretics) 
Thiazide (including combinations 65 65 
with triamterene) 
Triamterene mono-therapy 5 2 
Diuretic dose (%) 
<1 DDD 27 35 
=1 DDD 66 55 
> 1 DDD 7 10 
Duration of diuretic therapy (years) 7.2 ± 0.5 7.6± 0.6 
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Withdrawal group Control group 
Characteristic (n=102) (n=100) 
Co-medication (%) 
Digoxin 9 12 
Beta-blocker 27 23 
ACE-inhibitor 10 8 
Calcium antagonist 13 16 
Nitrates (daily use) 13 9 
COPO medication 13 11 
ECG(%) 
Left ventricular hypertrophy 3 
Atrial fibrillation 5 5 
Infarction 14 15 
Ventricular premature complexes 6 9 
Blood/serum parameters (mmel/I) 
Sodium (n=93, 99) 141 ± 0.3 141 ±0.3 
Potassium (n=93, 98) 4.1 ±0.04 4.1 ± 0.04 
Glucose (n=93, 99) 5.1±0.3 4.9 ± 0.2 
Uric acid (n=93, 99) 0.38 ±0.01 0.37 ± 0.01 
Cholesterol (n=93, 99) 6.4±0.1 6.3±0.1 
HDL-cholesterol (n=93, 99) 1.31 ± 0.04 1.27 ± 0.04 
Creatinine (micromol/!) (n=93, 98) 97 ± 2.8 95 ± 2.4 
DOD = Defined Daily Dose, Values are means ±SE, or proportions 
Secondary outcome variables were changes in heart failure symptoms, 
systolic and diastolic blood pressure level, increase in respiration rate 
after exercise, ankle circumference and body weight, and alterations in 
serum lipid, electrolyte, creatinine, uric acid and biood glucose levels. All 
outcomes were assessed in a double-bUnd way in all but six patients, 
whose diuretic therapy was restarted by their treating physician and the 
measurements in these patients were accomplished after breaking the 
code of the trial medication. 
Statistical analysis 
The frequency of fulfilling one of the criteria for requiring diuretic treat-
ment, and the Incidence of the combined outcome between the with-
drawal and the control group were compared by calculating risk differ-
ences with 95% confidence intervals and, in case of survival analysis, by 
log-rank tests. Effects on secondary outcome variables were assessed by 
calculating differences (with 95% confidence intervals) between the mean 
changes in these variables in the withdrawal and the control group. Mean 
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changes in variables were calculated by subtracting the baseline value 
from the last available value after randomization. Analyses were carried 
out by the intention-to-treat principle. Patients who fulfilled one of the 
criteria for requiring diuretic treatment during the trial had their last 
double-blind measurement of the secondary outcome variables carried 
forward to subsequent time points (carry-forward principle)." 'I'tests 
were used for continuous variables. A two sided P-value of less than 0.05 
was considered statistically significant. It was decided in advance to per-
form subgroup analyses according to age (65 to 79and <:80years), sex, and 
current indication of diuretic therapy (heart failure, hypertension and 
non-cardiac ankle oedema). Interaction tests were applied to compare 
subgroups. ,8 
Results 
From October 1991 until June 1993, 202 patients (53 men and 149 women) 
were included in the trial. The indications for diuretic therapy at the time 
of entry into the trial were heart failure (42%), hypertension (43%) and 
non-cardiac ankle oedema (14%). The mean age of the patients was 76 
years. Furosemide was used by 32% of the patients, thiazides (alone or in 
combination with triamterene) by 66% and triamterene alone in 2%. The 
mean duration that patients had been on diuretic therapy was 7.4 years. 
Of the 202 patients, I02 were randomly assigned to the withdrawal group 
and roo to the control group. The two groups were similar with respect 
to all relevant baseline characteristics (Table 7.1). 
Effect on primary outcome variable 
During the 6 months follow-up period, diuretic therapy was required in 
50 patients in the withdrawal group and in 13 patients in the control 
group (risk difference (RD) 360/0; 95% confidence interval (CI) 22 to 50%). 
Development of symptoms of heart failure was the most frequent reason 
to require diuretic therapy: 25 patients in the withdrawal group and 4 in 
the control group (Table 7.2). The probability of requiring diuretic ther-
apy in the two groups was highest during the first 4 weeks after with-
drawal of diuretic therapy (Figure 7.1). The combined outcome 'increase 
in heart failure symptoms and/or increase in blood pressure to a level 
higher than 160/90 mmHg' occurred in 83% of patients withdrawn from 
diuretic treatment, compared to 42% in the control group (RD 41%; 
95%CI27-55%). During the shldyperiod, none of the patients died or had 
to be admitted to hospital. 
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Table 7.2 
Occurrence of conditions requiring diuretic treatment after withdrawal 
of diuretic therapy in elderly patients 
Criterium 
All 
Heart failure* 
Hypertension* 
Subjective shortness of breath 
Non-cardiac ankleoedema 
Miscellaneous clinical conditions 
Other 
Withdrawal Control group 
group 
(n= 102) 
50 
25 
9 
6 
4 
3 
3 
13 
4 
5 
o 
2 
Risk difference 
(95% CI) 
36% (22 to 50) 
21% (11 to 31) 
4% (- 3 to 11) 
6% (1 to 11) 
3% (- 1 to 8) 
2% (- 2 to 6) 
1% (- 3 to 5) 
*" The reason for reinitiating was classified as heart failure if patients had heart failure scores 
> 4 points, and as hypertension if the mean value of 3 consecutive systolic or diastolic blood 
pressure measurements at different occasions was> 180 and/or 100 mmHg, respectively 
Effect on secondary outcome variables 
During the six months follow-up period a mean increase in the heart 
failure score of I,4 points (95% CI I,1 to I,7) was found in the withdrawal 
group compared to the control group (Figure 7.2a). This increase was 
reached at I month and was stable during the remaining period. Simi-
larly, the respiration rate after exercise and ankle oedema increased after 
withdrawal of diuretics (Figures 7.2b, 2C). An increase in body weight was 
observed after withdrawal with evidence of a rebound effect during the 
first month (Figure 7.2d). 
In comparison to the control group, the mean systolic and diastolic 
blood pressure levels gradually increased after withdrawal of diuretics by 
respectively 13.5 mmHg (95% CI 9.2 to 17.8) and 4.6 mmHg (95% CI I,9 to 
7.3) (Figures 7.2e, 7·2f). 
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Weeks after withdrawal of diuretics 
Kaplan-Meier analysis of the cumulative probability of successful withdrawal of elderly pa-
tients from diuretic therapy. Patients in the control group continued their diuretic medica-
tion, whereas this was replaced by placebo, in a double-blind way, in the withdrawal group. 
Patients who did not meet one of the predefined criteria for requiring diuretic therapy 
within the 6 months follow-up period are considered to besuccessfullywHhdrawn. Patients 
who fulfilled one of the criteria for requiring diuretic therapy during the dose-halving regi-
men (after randomization but before complete withdrawal of therapy) or during the 6 
months follow-up period are also considered to be unsuccessfully withdrawn 
Serum cholesterol fell after cessation of diuretic therapy (- 0.22 mmol/I; 
9S%CI-o.39 to -0.05), while HOL-cholesterol remained unchanged. The 
largest decrease in cholesterol levels (-0.4r mmol/I; 9S%CI-o.74 to-o.08) 
occurred in patients withdrawn from thiazides. Further, a statistically 
significant increase in serum sodium (1.2 mmol/I) and potassiulll (0.14 
mmol/I) and a decrease in blood glucose (0.6r) and uric acid (0.042 
mmol/l) levels was observed. Renal function improved as rellected by a 
decrease in serum creatinine (6.5 micromol/I) (Table 7.3). 
Subgroup analyses (Table 7.4) 
Women more often required diuretic therapy after cessation of diuretic 
therapy (RO 40%; 9S%CI2S to 55) than men (RO 26%; 9S%CI r to 51). After 
withdrawal of diuretics the heart failure score increased more in women 
(1.6 points; 9S%CI 1.0 to 2.2) than in men (0.7 points; 9S%CI -5 to lo9). 
Similarly, the relative increase in systolic and diastolic blood pressure was 
more prominent in women (r6.3/S.9mmHg) thanin men (S.3/-lo3 mmHg) 
(Interaction tests: P=0.03 and P=0.04). Patients who used diuretics be-
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Effect of withdrawal of diuretic therapy in the withdrawal group (drawn line) compared with 
the control group (dotted line) on heart failure score (Figure 7.2a), increase of respiration 
rate after exercise (Figure 7.2b), ankle circumference (Figure 7.2e), body weight (Figure 
7.2d), systolic blood pressure (Figure 7.2e) and diastolic blood pressure (Figure 7.2t). The 
ba rs represent 95% confidence interva Is. Follow-up data from patients who req u ired diuretic 
therapy during the follow-up period had their last double-blind measurement carried for-
ward to subsequent time points (carry-forward analysis) 
cause of heart failure required diuretic therapy more often than those 
with the current indication hypertension or non·cardiac ankle oedema; 
the risk differences were 57% (95%Cl 36 to 78), 21% (95%CI 2 to 40) and 
lO% (95%CI -II to 31), respectively. No marked differences were found In 
subgroup analyses according to age or duration of use of diuretic medi-
cation, apart from a larger increase in ankle oedema in the oldest age 
group. 
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Table 7.3 
Comparison of changes in serum/blood parameters after randomization in 
patients withdrawn from diuretic therapy (withdrawal group) and patients 
who continued diuretic therapy (control group)* 
Change from baseline 
Withdrawal Control Mean difference 
group group between withdrawal 
(n"102) (n"100) and control group 
Mean n Mean n 
change change 
±SD ±SD (95% 0) 
Serum sodium 0.5 ± 2.3 S7 -D.7i 2.1 89 1.2 (004 to 2.0) 
(mmol/I) 
Serum potassium D.17i 0.39 S6 0.03 ± 0.38 87 0.14 (0.01 to 0.27) 
(mmal/I) 
Serum creatinine -5.3 ± 13,3 S7 lo2± 7.8 88 -6.5 (-lOA to -2.6) 
(micromol/l) 
Serum uric acid - 0.045 ± 0.046 57 - 0.003 ± 0.035 89 -0.042 (- 0.056 to - 0.028) 
(mmol/l) 
Serum choles- -O.19± 0.48 57 0.03 ± 0.51 89 -0.22 (- 0.39 to - 0.05) 
teral (mmal/I) 
Serum HDl·cho· - 0.006 ± 0.153 57 -O.OOB± 0.152 88 0.002 (- 0.050 to 0.054) 
lesterol (mmal/I) 
Blood glucose -O.36± 2.26 S7 0.25 ± 1.39 89 -0.61 (- 1.26 to 0.07) 
(mmal/I) 
* In patients who were withdrawn from the study because of the development of heart failure symptoms, 
an 'end-at-study' blood sample was not taken before reinitiation of diuretics, since the clinical condition 
of the patient often did not allow the time needed for such an assessment Those patients were excluded 
from the analysis 
Blinding procedure and drug compliance 
The patients correctly guessed whether they were allocated to the with-
drawal or the control group in 62% of the cases, while their physicians 
guessed correctly in 65% of the patients. Patients on thiazides and 
furosemide guessed correctly 56% and 74% of the time, respectively. The 
corresponding proportions for the trial doctors were 66% and 65%. On 
basis of the serum levels of chlorthalidone, triamterene and furosemide 
at baseline and at completion of the trial, drug compliance of the 
patients during the trial was estimated to be IOO% in the withdrawal 
group and 90% in the control group. 
Table 7.4 
Effects of withdrawal of diuretics in subgroups of patients by sex, and current indication for diuretic therapy. 
Diuretics reinitiated (%) 
Diuretics required because of HF (%) 
Change in heart failure score (points) ... 
Change in systolic blood pressure (mmHg)* 
Men 
(n=51) 
Diff. (95% CI) 
26 (1 to 51) 
12 (-6 to 30) 
0.7 (- 0.5 to 1.9) 
5.3 (-3to16) 
Change in diastolic blood pressure (mmHg)'" -1.3 (-8 to 5) 
Change in ankle circumference (em)" 0.4 (0.0 to 0.8) 
... Carry~foreward analysis 
Sex 
Women 
(n=151) 
Diff. (95% CI) 
40 (25 to 55) 
23 (11 to 35) 
1.6 (1.0 to 2.2) 
16.3 (l1to 21) 
5.9 (3 to 9) 
0.5 (0.3 to 0.7) 
Diff.::: difference between the withdrawal group and the control group 
Heart 
failure 
(n=84) 
Diff. (95% Cl) 
57 (36 to 78) 
39 (21 to 57) 
2.3 (1.5 to 3.1) 
12.1 (6to18) 
32 (-1 t08) 
0.5 (0.2 to 0.8) 
Indication for diuretic therapy 
Hyper· Non-cardiac 
tension ankle oedema 
(n=88) (n=28) 
Diff. (95% CI) Diff. (95% Ci) 
21 (2 to 40) 10 (-11t031) 
5 -7to 17) (-18to 20) 
0.6(- 0.2 to 0.9) 0.8 (- 0.7 to 2.3) 
14.8 (8 to 22) 15.8 (4 to 28) 
5.2 Q to 9) 4.8 (-3to13) 
0.4 (0.2 to 0.6) 0.4 (- 0.1 to 0.9) 
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Discussion 
Our findings indicate that withdrawal of long-term diuretic therapy in 
elderly patients without manifest heart failure or hypertension is often 
accompanied by occurrence of symptoms of heart failure or a rise in 
blood pressure level. The predefined criteria to restart diuretic treatment 
were fulfilled in 49% of patients withdrawn from diuretics and in I3% of 
those continuing diuretic therapy (RD 36%; 950/0C1 22 to 50). This risk 
difference was most pronounced in those prescribed diuretics for the 
indication heart failure. 
The vast majority of clinical conditions requiring reinitiation of diuretic 
therapy occurred during the first 4 weeks after withdrawal. This indicates 
that our withdrawal regimen might have been to brusque and a certain 
degree of rebound fluid retention cannot be ruled out. A more prudent 
weaning-off procedure could have produced a higher rate of successful 
withdrawal from diuretic therapy. 
In our study, withdrawal compared to continuation of diuretic medica-
tion of diuretics led to a considerable increase in systolic and diastolic 
blood pressure levels. A marked decrease in blood pressure levels in the 
control group constitutes a substantial part of this blood pressure effect. 
This phenomenon could be explained by the fact that blood pressure 
measurements were performed at the patient's homes, and patients pro-
greSSively got used to the procedures during follow-up visits. This stresses 
the indispensability of a control group. The blood pressure effects in this 
study are similar to those reported in four earlier double-blind random-
ized trials of withdrawing therapy in treated normotensive hypertension 
patients. '9,W."," It is difficult to draw conclusions about the harm or ben-
efit of the average rise in blood pressure levels we observed in patients 
that were successfully withdrawn from diuretic treatment. In this popula-
tion of patients with a mean age of 76 years and mean baseline blood 
pressure levels of I47/81 mmHg, the observed increase In blood pressure 
level may be considered an unwanted effect leading to an increased risk 
of cardiovascular disease, or may reflect a beneficial correction of relative 
dehydration. 
We found a remarkable sex difference in the effect of withdrawal of di-
uretic therapy on blood pressure level and on the probability of develop-
ing heart failure symptoms. Because, as far as we know, only marginal sex 
differences of the effect of thiazides on blood pressure levels and no dif-
ference on diuresis were reported In the literature, no clear explanation 
for this finding exists. '3,'4 
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Withdrawal of diuretics caused an average decrease in serum cholesterol 
at the end of the 6 months follow-up period of 0.22 mmol/l (~3.4%) and 
was most pronounced after discontinuation of thiazides (0.41 mmol ~ 
6.4%). This is an interesting finding since it has been postulated that any 
cholesterol rising effect of diuretics would disappear after extended use 
of the drug and the mean duration of diuretic usage prior to inclusion 
into this trial was 7 years.,"·"·,6.,, The effect of cessation of diuretic ther-
apy on serum parameters could only be determined in participants whose 
diuretic therapy had not to be restarted because of manifest heart failure 
during the trial period. The worsened clinical condition of these patients 
left no time to organize blood sampling before restarting diuretic therapy. 
It is unlikely that this selection had an important influence on our find-
ings, because similar distributions of the baseline electrolyte and choles-
terol concentrations existed in the 46 patients with only baseline mea-
surements and in the 146 patients with additional measurements after 
withdrawal. 
This study included patients that used diuretics for heart failure, hyper-
tension or non-cardiac ankle oedema. The reason for studying such a 
heterogenic group was implicit to our research objective: to assess the 
proportion of all diuretic-treated elderly patients who could successfully 
be withdrawn from their diuretic therapy. As expected, subgroupanalyses 
demonstrated that after withdrawal of diuretic therapy development of 
symptomatic heart failure most frequentiy occurred among patients pre-
scribed diuretics for the indication heart failure (RD 57°/0). Analogously, 
hypertension was the most common reason for requiring diuretic therapy 
after withdrawal in patients using diuretics for hypertension. Interest-
ingly, however, increase in heart failure symptoms and blood pressure 
levels occurred in all three indication groups, including patients with 
non-cardiac ankle oedema as current indication for diuretic therapy. (Ta-
ble 7.4). Hypertension is a major risk factor for heart failure and appar-
ently many of the patients on diuretic treatment for hypertension had 
gradually developed asymptomatic heart failure. In addition, some pa-
tients who received diuretics because of non· cardiac ankle oedema may 
have been suffering from (asymptomatic) heart failure. 
The absence of chest X-rays and echocardiography were limitations in 
the assessment and classIfication of heart failure. Since the aim of our 
pragmatic study was to assess which proportion of patients receiving 
long-term diuretic therapy could be withdrawn from their medication in 
a non-hospital setting, only diagnostiC procedures applicable at the gen-
eral practitioner's surgery or at the home of the patients were applied. 
Moreover, a substantial number (>30%) of the patients in thIs study were 
over 80 years of age and others were disabled and home-bound and we 
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felt that hospital-based diagnostic procedures would severely impair the 
willingness of patients to cooperate, and thus affect the generalis ability 
of our results. In addition, the heart failure symptom score list that we 
used appeared a valid and feasible instrument in a recent validation 
study. (see previous footnote) 
Many earlier studies on withdrawal of diuretics did not include a compar-
ison group, and of the controlled trials only a minority included placebo 
treatment. ",,8,'9 The need of a control group to take into account the 
nabtral history of the conditions studied, is clearly illustrated by the re-
sults of our trial.30 Although 83 % of the patients in the withdrawal group 
developed heart failure symptoms or hypertension after withdrawal, this 
proportion was as high as 42% among the patients in the control group 
who continued to receive diuretic therapy. A placebo· controlled design 
in drug withdrawal studies, as in drug efficacy trials, is necessary to isolate 
the pharmaceutical effect from the placebo.effect and to exclude observa-
tion bias. If our study would not have been placebo-controlled it would 
have suggested a too high failure rate. In fact, 'verum-controlled trials' 
would be a more appropriate classification of such studies, because pa-
tients assigned to the verum arm act as the reference group. Although 
appropriate methods were used to ensure a double-blind conduct of the 
trial, a potential problem in drug withdrawal studies is that both patients 
and doctors are aware of the effects of the medication, and may recognize 
the trial arm to which the patient was randomized. In our study com-
pletely effective blinding could not be achieved (for example 62% of the 
patients correctly guessed the trial arm they were in), but this is unlikely 
to have induced important bias. 
The analysis of data of secondary outcomes, e.g. heart failure symptoms 
and blood pressure levels, was carried out according to the carry-forward 
principle. Patients who were withdrawn from the study had their last 
double-blind measurements carried forward to subsequent time points. 
This technique most closely approaches aformal intention-to-treat analy-
sis. We realize that carrying forward of the last available measurements 
introduces virtual data. The alternative, however, is on-treatment analy-
sis which is more likely to introduce bias. Nevertheless, we did perform 
such an analysis, and it disclosed similar results. Formal intention-to-
treat analysis would have been useless because of large dilution effects 
caused by reinitiating diuretic therapy in a considerable proportion of the 
study population. 
The proportion of patients that could be successfully withdrawn from 
diuretic treatment in our study was not as large as reported in previous 
sbldies. Twoearliercontrolled randomized trials of withdrawal of diuretic 
7 Withdrawal oflollg-term diuretic medicatioll ill elderly patiellts ro7 
therapy in the elderly were performed, one in m6 patients in geriatric 
hospital wards and one in 77 patients in geriatric institutions and the 
follow-up periods in these studies were 3 and 12 months. ,8,'9 The propor-
tions of patients that could be successhllly withdrawn from diuretic treat-
ment were 76 and 71%, respectively, compared to 49% in our study. The 
risk differences of' clinical need for reinitiating diuretic therapy' between 
the placebo- and the control group in these studies were only 16% (95% 
CI 2 to 30) and 8% (95% CI -12 to 28), while we found a larger difference 
of 36% (95% CI 22 to 50). The difference between these two earlier trials 
and the present one are most probably explained by the selection of the 
institutionalized patients in the former studies. Different clinical criteria 
to restart diuretics may be an alternative explanation for the difference. 
Inappropriate medication use represents important quality of care prob-
lems in the elderly.3' The potential adverse effects and interactions of 
diuretics in elderly patients justify regular evaluation of the possibility of 
cessation of diuretic medication. Our study, however, shows that with-
drawal of long-term diuretic treatment in elderly patients leads to the 
occurrence of symptoms of heart failure or an increase in blood pressure 
levels to hypertensive values in the majority of cases. In selected patients, 
withdrawal may be successful, but careful monitoring is needed, notably 
during the initial four weeks. In patients with a history or signs and 
symptoms of heart failure cessation of diuretic therapy should generally 
not be tried. If in hypertensive patients, blood pressure is well regulated 
during at least one year, withdrawal is warranted. Patients with non-car-
diac oedema should preferably not be treated with diuretics, and thus 
withdrawn. However, a relatively small but realistic risk of manifest heart 
failure after withdrawal of diuretic therapy in these patients as in hyper-
tensive patients exists, because ventricular dysfunction could have been 
masked by diuretic therapy. This implies close monitoring for possible 
heart failure signs and patients should be instructed to perform body 
weight measurements every morning before breakfast, notably in the first 
month after down titration or withdrawal of diuretics. An increase of 
more than two kilograms, or increasing dyspnea are indications for a 
physician's assessment of the clinical condition of the patient on the 
same day. 
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8 General discussion and implications for medical practice 
The main studies in this thesis focus on the possibility to withdraw long-
term diuretic therapy in elderly patients in the general practice setting. 
These studies were initiated because it seemed that, in the elderly, diu-
retic prescriptions are often repeated unnecessarily, for many years. Fur-
ther, the available national clinical gUidelines on the management of 
'heart fail ure' and 'hypertenSion' are described in this thesis, to assess the 
current role of diuretic therapy. By critically reviewing the current role of 
diuretics and exploring the possibilities to withdraw long-term diuretic 
medication, these studies aim to contribute to rational and appropriate 
prescribing of diuretic therapy. In this chapter, the conclusions from the 
studies included in this thesis and the implications for medical practice 
will be discussed. 
Conclusions from the randomized withdrawal study 
Patients in and around Schoonhoven, over 65 years of age, and receiving 
long-term diuretic therapy were enroled in a randomized trial to shtdy 
the possibility of withdrawal of diuretic therapy. Patients with clear indi-
cations to continue diuretic therapy (manifest heart failure or hyperten-
sion) were excluded. In 52 of lO2 patients in the withdrawal group, with-
drawal succeeded. The other 50 patients required resuming of diuretic 
therapy (which in 25 cases was attributable to the occurrence of symp-
toms of heart failure), while in the control group (those who continued 
their diuretic therapy), only 13 of lOa patients required additional diuret-
ics (four because of symptoms of heart failure). This amounted to a risk 
difference (RD) of events leading to requirement of diuretic therapy of 
36%. These findings may lead to two, rather opposite conclusions. At the 
one hand, 50% of the patients were successfully withdrawn from diuretic 
therapy, an argument in favour of regular assessment of the possibility 
of cessation of diuretic therapy in medical practice. At the other hand, 
the risk of withdrawal appeared to be substantial: 25% of the patients 
developed symptoms of heart failure, a potentially dangerous clinical 
situation. Thus, the trial demonstrates that long-term diuretic therapy is 
unnecessary in 50% of the patients, but that withdrawal of long-term 
diuretic therapy is a riskfnl medical intervention reqniringcareful moni-
toring of patients. Before the trial was initiated, it was anticipated that 
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more patients could be withdrawn without negative clinical effects. For 
example, withdrawal from diuretic therapy caused a relatively large mean 
increase in systolic and diastolic blood pressure of 13.5 and 4.6 mmHg, 
respectively, which was remarkably more pronounced in women than in 
men (16.3/5.9 versus 5.3/'1.3, interaction test: P<0.05). For this gender dif-
ference no satisfactory explanation exists. Large hypertension trials did 
not show a difference in the blood pressure lowering effect or efficacy of 
diuretics between the sexes.'" 
As expected, the risk of heart failure was largest in patients with a history 
of heart failure, but remarkably, also patients with hypertension or non-
cardiac ankle oedema as the indication for diuretic therapy, were at risk 
of heart failure after withdrawing diuretic therapy. A not always recog-
nized heart failure component may have played a role in these patients. 
Further, slowly developing heart failure may have been masked by long-
term diuretic treatment. 
Met/wdologicallimitations of tile trial 
The randomized, placebo-controlled, double-blind, design of our trial 
assured a high level of internal validity, Nevertheless, several remarks 
about methodological limitations should be made. First, the high number 
of patients developing heart failure during the very first weeks after with-
drawal, together with the course of the mean body weight in this period 
(Figure 7.zd), indicates that rebound effects may have been rather strong, 
Perhaps, our dose down titration was not prudent enough, and appar-
ently was not capable to prevent such rebound effects. If cessation of 
therapy had been carried out over a more prolonged period, we might 
have reached a higher success rate of withdrawal. 
Because the aim of the trial was to assess the pOSSibility of reducing long-
term diuretic therapy, patients on long-term diuretic treatment were re-
cruited regardless of the indication for treatment. This resulted in a heter-
ogenic patient population of hypertension patients, heart failure patients 
and patients with non-cardiac oedema. The diagnosis at the start of the 
treatment could not always be reliably retrieved from the medical files 
and the current indication of treatment, based on information provided 
by the general practitioners was taken as the criterium for the subgroup 
analyses. Although this information is expected to be accurate, no further 
diagnostic tests, e.g echocardlography, were carried out to verify the Indi-
cations reported by the general practitioners. This may have introduced 
some inaccuracy in the analyses in subgroups of indication for diuretic 
therapy. 
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It is impossible to obtain complete blinding with a fast and strong acting 
drug such as furosemide. As expected, patients on furosemide correctly 
guessed the content of their study medication more frequently (78%) 
than expected by chance. We believe, however, that even a partially ef-
fective blinding remains a useful tool to diminish extraneous (non-phar-
macological) effects of the withdrawal procedure and to limit observer 
bias. 
The external validity of our Shldy was positively influenced by two im-
portant factors. First, we were able to trace all patients on long-term diu-
retic treatment in a coherent geographic area covered by eight general 
practices. Second, a number of characteristics of 130 eligible, but not in-
cluded patients was assessed and compared to the patients included in 
the trial. These patients could not be included because of the following 
reasons: no informed consent (41), physician's veto (16), no placebo avail-
able (40), fixed drug combinations (25), other (8). This group appeared to 
be somewhat older, and used their diuretic medication somewhat longer 
than the patients included in the trial. Importantly, the diagnoses heart 
failure and hypertension, and the proportion of females were essentially 
the same. These results indicate that generalis ability of the trial was not 
affected by non-inclusion of a number of eligible patients. External valid-
ity is also determined by the representativeness of our study population. 
Considering the characteristics of the patient population, the numbers 
of patients on diuretic therapy, and the indications for diuretic therapy 
in our study, the study population seems representative of the general 
practice population at large. 
When conclusions are drawn about the proportion of patients that can 
be withdrawn from diuretic therapy, it should be kept in mind that of 470 
patients on long-term diuretic therapy, we excluded II7 patients because 
of heart failure and 21 because of poorly regulated hypertension. These 
29% were considered to require diuretic therapy and the results of the 
trial should not be extrapolated to this type of patients. 
The guidelines 
Evidence based medicine is a key word in modern medical practice. The 
increasing availability of a scientific basis for diagnostic and therapeutic 
procedures is a laudable development as such, but sometimes the amount 
of new informatlon may be confusing to practising physicians. 
Comments and editorials in authoritative, high quality journals are help-
ful in summarizing and interpreting important new research findings, 
but they can be very contradictory. National clinical guidelines, based on 
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scientific evidence and consensus among doctors seem the best way to 
bridge scientific evidence and medical practice, and hopefully the role of 
national clinical guidelines in medicine will increase during the coming 
years. 
The development of nearly sixty national clinical guidelines in many 
different fields of medicine, during the last 7 years by the Dutch College 
of General Practitioners (NHG) is a tremendous achievement. These 
guidelines are exclusively developed by, and intended for general practi-
tioners. When on a certain topic a multidisciplinary national guideline 
already existed, this has inevitably led to the existence of more than one 
national guideline in the country. Also in the U.S.A. more than one na-
tional guideline on certain issues exist, for instance in heart failure. The 
existence of more than one national guideline on a certain clinical topic 
per country, with often contrasting recommendations, is undesirableand 
prone to create confusion instead of solving it. The policy of the Dutch 
College of General Practitioners (NHG) has been to develop their guide-
lines separate from medical specialists. Presently the quality of their 
guidelines is broadly recognized and the time seems ripe for more coope-
ration with specialists, resulting in 'transmural guidelines'. This would 
overcome the major problem of the existence of multiple national guide-
lines. 
Role of diuretic therapy in heart failure guidelines 
From the six national clinical guidelines studied it may be concluded that 
diuretics remain the basis of drug therapy in the treatment of symptom-
atic heart failure, and the addition of ACE-inhibitors to diuretic treat-
ment may further improve the condition and the prognosis of the pa-
tient. It remains unclear whether elderly patients with mild forms of 
heart failure (NYHA II), who, on low dosages of diuretics, are free of 
symptoms, should be treated with monotherapy of diuretics, mono-
therapy of ACE-inhibitors, or a combination of diuretics and ACE-inhibi-
tors. A randomized trial, preferably in the general practice setting, is 
needed to solve this question. 
Role of diuretics in hypertension guidelines 
Most of the evidence from randomized controlled trials about the reduc-
tion of the risk of cardiovascular morbidity and mortality by antihyper-
tensive treatment is based on treatment with diuretics. The same magni-
tude of efficacy has been demonstrated of E-blockers, albeit in a smaller 
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number of trials. Evidence from randomized controlled trials about the 
efficacy of other classes of antihypertensive drugs, such as calcium antag-
onists, ACE-inhibitors, a-blockers, or angiotensine-II antagonists does not 
exist. For this reason diuretics or B-blockers are the drugs of first choice 
in the treatment of hypertension. 
In this context it is surprising, that the prescription pattern in medical 
practice does neither fit with the results of the large trials, nor with the 
recommenda tions of the national clinical guidelines, M and that notwith-
standing the lack of trials assessing their influence on cardiovascular mor-
bidity and mortality, several newer classes of antihypertensive drugs have 
become increasingly popular. In the case of calcium antagonists, this 
happened despite suggestions of harmful effects_s.6.,.8.9.,",n,,, Several recent 
studies produced additional evidence of an increased risk of severe side 
effects in hypertensive patients receiving short-acting dihydropyri-
dines'3,,,,,s,,6,,, although the methodology of these studies has been criti-
cized. In principle, these newer classes of antihypertensive drugs should 
not be prescribed as drugs of first choice in the treatment of hyperten-
sion, until proper evidence of long-term studies demonstratIng their su-
periorityor equality to diuretics and B-blockers becomes available. 
Potential factors that might explain the relatively high prescribing rates 
of those newer antihypertensive agents, are the erroneous idea that low-
ering blood pressure will always lead to reduced cardiovascular morbidity 
and mortality, and the idea that newer drugs, with new mechanisms of 
action, are better than older ones. Also the much higher costs of the 
newer (patented) drugs did not prevent their fast and thorough penetra-
tIon into the market. Most probably the commercial activities of pharma-
ceutical industries largely influenced prescription behaviour of many 
physicians, whereas the impact of independent national clinical guide-
lines is not large enough. Possible solutions of this problem have many 
political aspects and are not to be discussed here. Others have elaborated 
on it nl0re extensively,I8,I9t20,2I,22,23 
Drug withdrawal studies 
Because of the potentially important clinical consequences of drug with-
drawal, studies assessing the effects of withdrawal need to meet the same 
methodological requirements as shldies assessing the efficacy of new 
drugs. Uncontrolled withdrawal studies are inadequate to study the ef-
fects of drug cessation, in the same way as uncontrolled studies generate 
insufficient evidence about drug efficacy. Isolation of the pharmacologi-
cal effect of drugs from natural course effects, extraneous effects and ob-
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server bias is as important in drug withdrawal studies as it is in efficacy 
trials. It is undesirable that natural course or extraneous effects may lead 
to the erroneous conclusion that a pharmacon cannot be discontinued, 
while, phannacologically, the withdrawal is safe. Unnecessary continua-
tion of long-term drug therapy would be the consequence. 
In reports of randomized trials of drug withdrawal, the tendency exists 
to express the proportion of successful withdrawal, as the proportion of 
successful withdrawal in the withdrawal group alone (as if no control 
group was available). This is rather odd, because one would never express 
the efficacy of a new intervention, as studied in an efficacy RCT, without 
correcting for extraneous effects (through comparison with the control 
group). Thus, analogously to efficacy RCTs, when reporting the propor-
tion of successful withdrawal of treatment, the control group of with-
drawal studies should not be forgotten. In chapter 4 of this theSis, an 
alternative effect measure for withdrawal studies is proposed: the 
adjusted success rate. This rate takes into account, the proportion of un-
successful withdrawal, attributable to natural course or extraneous ef-
fects, which can be estimated by including a verum-treated control 
group. 
In our trial, this adjusted success rate is 64%. The meaning of this figure 
is that in 64% of the patients diuretics may be withdrawn, without unfa-
vourable effects attributable to the mere absence of the phannacon. Or, 
in other words, this proportion of successful withdrawal would have been 
reached if natural course/extraneous effects were absent. This figure is 
considerably higher and more encouraging than 5I% successful with-
drawal observed in the withdrawal group alone. 
Withdrawing patients from diuretics in medical practice 
To prevent overmedication and polypharmacy, the need for continued 
drug treatment should be evaluated regularly. For this purpose, the fol-
lowing checklist'· could be applied: 
Was the indication at the start of the treatment correct? 
Is the indication still present? 
Did a contra-indication evolve? 
Are adverse effects present? 
Are interactions possible? 
Do the advantages of continued treatment outweigh the disadvan-
tages? 
Are the risks of withdrawal acceptable? 
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The withdrawal of diuretic treatment needs extra attention, because It is 
a relatively riskful procedure. Heart failure, is the most dangerous poten-
tial complication (see Table 7.4 for the magnitude of risks in subgroups 
of patients). In the trial presented in this thesis predicting factors for de-
velopment of symptomatic heart failure after cessation of diuretic ther-
apy were a history or symptoms of heart failure, female sex, and old age. 
By applying multiple logistic regression analysis it can be estimated that 
a man, 65 years of age, receiving diuretic therapy because of hyperten-
sion, and no history or symptoms of heart failure has a risk to develop 
heart failure after withdrawal of only 2.6%, whereas a woman, 84 years of 
age, receiving diuretic treatment because of heart failure, with minor 
symptoms or signs of heart failure has a risk of 84% to develop heart fail-
ure after withdrawal. This demonstrates the enormous difference in indi-
vidual risk of heart failure after withdrawing diuretic medication and the 
importance of careful consideration of a patient's characteristics before 
the decision to withdraw diuretics is made. 
Recommendations for medical practice 
in patients with a history, signs or symptoms of l1eart failllre withdrawal 
should generally not be tried. However, periodical down titration of the 
dose to avoid underhydration may be undertaken, albeit under strict 
monitoring of possible signs of heart failure. Patients should be instruc-
ted to perform body weight measurements every morning before break-
fast, at least in the first month after down titration or withdrawal of diu-
retics. Notably, an increase of more than two kilograms, or increasing 
dyspnea indicates an enhanced risk of developing manifest heart failure, 
and is an indication for a physician's assessment of the clinical condition 
of the patient on the same day. 
If in l1ypertellsive patients blood pressure has been well regulated during 
at least a 1 year, withdrawal maybe tried. In cases of long-term treatment, 
latent heart failure may be masked by diuretic therapy and manifest heart 
failure may develop after withdrawal of therapy. In many patients strict 
monitoring is recommended, according to the same criteria as in heart 
failure patients. Women will generally show larger increases in blood 
pressure than men, and a higher risk of developing heart failure. All pa-
tients remain at risk of an increase in blood pressure levels to hyperten-
sive values and regular blood pressure monitoring, initially every 3 
months, and later every 6 to 12 months, should be continued for years. 
Patients with lIoll-cardiac oedema should preferably not be treated with 
diuretics, and thus withdrawn. A small but realistic risk of heart failure 
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after withdrawal of diuretic therapy in these patients, however, implies 
a need for close monitoring for possible heart failure signs. Also in this 
group of patients, masking (by the diuretic therapy) of latent heart failure 
that may have developed gradually over the years, is the most likely ex· 
planation for the observed risk of heart failure after drug cessation in 
these patients. The need of daily body weight measurements depends of 
clinical judgement of the risk of heart failure. 
Final conclusion 
A.D. 1997, diuretics are still drugs of first choice in the treatment of heart 
failure and hypertension. Since diuretics are widely prescribed, especially 
in elderly patients, unnecessary use of diuretics is not a rare phenome-
non. This merits a critical assessment of the possibility to discontinue 
prolonged diuretic therapy in individual patients. Cessation of diuretic 
therapy in heart failure patients should not be encouraged because of the 
risk of development of manifest heart failure, although active dose titra-
tion is useful. The possibility of withdrawal in patients receiving diuretic 
therapy for the indications hypertension and non-cardiac ankle oedema 
should regularly be evaluated. However, the risk of the occurrence of 
heart failure after withdrawal of diuretic treatment in patients with hy-
pertension or non-cardiac oedema cannot be ruled out. Thus, careful 
monitoring after withdrawal is warranted, especially during the first 
month. 
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9 SUMMARY 
Diuretics stimulate urine production by the kidney, and are very useful 
drugs to evacuate excess water and salt from the body. After the introduc-
tion of chlorothiazide in I957, diuretics rapidly became one of the most 
frequently prescribed classes of drugs. Approximately 20% of all men and 
women of 65 years or older, and 50% of those over 80 years of age, use 
long-term diuretic medication. Diuretics are usually divided in 3 classes: 
thiazides, loop diuretics and potassium sparing diuretics. Heart failure 
and hypertension are the major indication for diuretics. Although, heart 
failure and hypertension are conditions with a high prevalence in elderly 
people, prescriptions for diuretics often seem to be repeated without 
evaluation of the need for prolonged treatment. Although relatively safe 
drugs, potentially dangerous adverse effects of diuretics have been re-
ported. Unnecessary therapies should always be avoided and diuretic 
therapy is no exception to this rule. The objective of the main study 
presented in this thesis, is to determine the proportion of elderly patients 
on long-term diuretic therapy that may be successfully withdrawn from 
this therapy. Further, the current role of diuretics in the treatment of 
heart failure and hypertension was shtdled. 
In Chapter 2, six recently published national clinical gUidelines, one from 
Sweden, one from Canada, two from the USA, and two from the Nether-
lands, were reviewed to assess the current role of diuretics in the treat-
ment of chronic heart failure. In all guidelines diuretics playa key role in 
the treatment of heart failure. In five guidelines combined therapy with 
diuretics and ACE-inhibitors is recommended. The guideline of the 
Dutch general practitioners (NHG-Standaard) takes an exceptional posi-
tion by recommending monotherapy with diuretics as a first step in the 
therapy of patients with mild heart failure (NYHA II). All guidelines rec-
ommend thiazide therapy in patients with mild heart failure, which 
should be replaced by furosemide when stronger diuretic effects are 
needed. Active down titration of diuretics in clinically stable patients and 
up-titration in case of symptoms of volume overload Is advised in all 
guidelines. Combination of thiazides and furosemide, and in some cases 
spironolactone are recommended, for patients with persistent oedema, 
in all guidelines. Recommendations for diuretic treatment of heart failure 
patients with predominantly diastolic ventricular dysfunction differ re-
markably in the various guidelines: ranging from 'first choice' to 'to be 
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avoided'. In conclusion, major differences between the six guidelines 
exist regarding the role of monotherapy with diuretics and treatment of 
patients with heart failure with predominantly diastolic ventricular dys-
function. These contrasting recommendations are attributable to differ-
ences in interpretation of the results of the pUblished trials, and, in the 
case of diastolic dysfunction, of often premature and contradicting scien-
tific evidence. 
In Chapter 3, five recently published national clinical guidelines from the 
Netherlands, Canada, Great Britain and the USA were reviewed to assess 
the current role of diuretics in the treatment of mild to moderate hyper-
tension. The Dutch Gp, American, British and Canadian guidelines re-
commend to prescribe diuretics or E-blockers as first choice drugs. Be-
cause of the lack of randomized trials assessing the efficacy of newer 
classes of drugs, such as ACE-inhibitors and calcium antagonists, these 
antihypertensives are not recommended as drugs of first choice. The Ca-
nadian and British guidelines prefer thiazides over E-blockers in elderly 
patients. Hypercholesterolemia is not considered an argument against 
thiazide therapy and the minor increase of plasma cholesterol following 
thiazide administration is perceived as clinically irrelevant. In diabetes 
patients diuretics are not considered to be absolutely contraindicated, but 
because of the negative influence of diuretics on glucose metabolism, 
most guidelines recommend other antihypertensive drugs as first choice 
agents. Combinations of thiazides and potassium sparing diuretics are 
not generally advised as first choice agents, but the Canadian and British 
guidelines mention them as possible first choice therapy in elderly pa-
tients. In the light of recent scientific evidence their role seems to be 
somewhat undervalued in the guidelines. For elderly hypertension pa-
tients, there is substantial evidence that potassium sparing combinations 
are at least equally effective as thiazides. 
In Chapter 4 several methodological aspects of 'drug withdrawal trials' are 
discussed. The typical aim of these studies is to determine potential possi-
bilities for reducing unnecessary and possibly harmful medication. A 
major pitfall is drawing conclusions about drug efficacy by extrapolation 
and reversal of the effects of drug withdrawal. We have claimed that the 
randomized controlled trial design is equally desirable in drug with-
drawal studies as in any drug efficacy study. The index group is formed 
by patients on placebo medication, whereas the control group is formed 
by patients on active medication; by this reversal in comparison to effi-
cacy trials, it is better to speak of 'verum' - controlled instead of placebo-
controlled trials. Blinding of patients and doctors is required, when the 
purpose is to assess the effect of withdrawal of the pharmacological sub-
strate. Alternative effect measures, that take 'success' instead of 'risk' as 
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a starting point, may be helpful tools to estimate the clinical relevance of 
the results of withdrawal trials. Finally, the equal, clinical importance of 
avoiding of type 1 and type II errors, and the consequences for trial sizes 
of withdrawal studies is discussed. Drug withdrawal studies are an impor-
tant tool to learn in what cases overmedication can be curtailed, but they 
should be well designed. 
In Chapter 5 the accuracy of the Omron HEM403C blood pressure device 
was assessed. A comparison was made with a Hawksley random zero 
sphygmomanometer. Blood pressure was measured with both meters 
connected to one arm-cuff by means of aT-connector. Ib assess the level 
of agreement of the Om ron HEM403C with the random zero meter, 
blood pressure was measured in 212 subjects. Systolic and diastolic read-
ings with the Omron HEM403C were on average respectively I mmHg 
(sd 9, 9S% CI 0.4-2.2) and 4 mmHg (sd 8, 9S% CI3.6-S.I) higher than those 
with the random zero meter. According to the criteria of the British Hy-
pertensionSociety the Omron HEM403Cis (marginally) accurate enough 
to be recommended for those clinical and research purposes that are in 
need of automatic measurements. 
An uncontrolled study (Chapter 6) in the practice of the author preceding 
the execution of a large randomized trial (Chapter 7) was performed to 
assess the feasibility of a study on the cessation of diuretic therapy and 
to estimate the proportion of patients that could successfully be with-
drawn. The effects of withdrawal on blood pressure, heart failure (HF) 
score, edema, body weight and subjective complaints were monitored 
during the 6-months follow-up period. Approximately 20 % of all people 
of 6s years or older were on maintenance therapy with diuretics. From 38 
available patients 22 were excluded, mainly because of symptoms of heart 
failure or hypertension. One patient refused to participate. Thus, in IS 
patients the diuretic medication was withdrawn under careful medical 
monitoring conditions. After 6 months, 6 patients were still without diu-
retic therapy. Diuretic therapy had to be resumed in 9 cases, because of 
congestive heart failure (n=I), hypertension (n=3), bronchial asthma 
(n=I), increased ankle edema (n=2) and subjective complaints (n=2). The 
withdrawal of diuretics caused an increase in mean systolic blood pres-
sure, HF-score, body weight and ankle edema. We concluded that mainte-
nance diuretic therapy in elderly patients in general practice could be 
successfully withdrawn in selected cases. 
Consequently, we performed a double-blind randomized trial to assess 
the effects of withdrawal from long-term diuretic therapy in the elderly 
(Chapter 7). Of 470 patients on long-term diuretic treatment, identified 
in eight general practices, 268 were excluded, mainly because of symp-
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toms of healt failure or hypertensive blood pressure levels. In total, 202 
patients from eight general practices were randomly allocated to either 
placebo (withdrawal group) or continuation of their diuretic treatment 
(control group) during a 6 months period. Occurrence of clinical condi-
tions requiring diuretic therapy based on fixed criteria, was the main 
outcome of the trial. During the 6 months follow-up period, resuming of 
diuretic therapy was reqUired in so patients in the withdrawal group 
while additional diuretics were required in 13 patients in the control 
group (risk difference (RD) 36%; 9S%CI 22 to so%). The risk of requiring 
diuretics was most prominent in patients who used diuretics for the indi-
cation heart failure (RD S7%). Cessation of diuretic therapy caused a 
mean increase in systolic and diastolic blood pressure of 13.S (9S%CI 9.2 
to 17.8) and 4.6 mmHg (9S%CI I.9 to 7.3), respectively. Cessation of di-
uretic medication further lowered serum cholesterol, creatinine and uric 
acid levels and increased serum sodium and potassium levels. These re-
sults indicate that withdrawal of long-term diuretic treatment in elderly 
patients leads to symptoms of heart failure or increase in blood pressure 
levels to hypertensive values in the majority of cases. In selected patients, 
in particular those with hypertension or non-cardiac oedema as the indi-
cation for diuretic therapy, withdrawal may be successful, but careful 
monitoring is needed, notably during the initial four weeks. 
The general discussion (Cllapter 8) elaborates on a number of topics de-
scribed in this thesis, for example the importance of national guidelines, 
the discrepancies between the recommendations in national guidelines 
for hypertension and the actual prescription pattern, and the potential 
implications for general practice of the results of the withdrawal studies 
included in this thesis. Finally, recommendations to guide decisions to 
withdraw long-term diuretic medication in medical practice, induding 
suggestions concerning monitoring requirements after withdrawal, are 
given. 
1 0 Samenvatting 
Diuretica stimuleren de nieren tot urineproductie en zijn nuttige genees-
middelen wanneer de uitscheiding van overtollig water en zout uit het 
lichaam moot worden bevorderd. Na de introductie van chloorthiazide 
in 1957 behoorden diuretica al spoedigtot de groep meestvoorgeschreven 
geneesmiddelen. Ongeveer 20% van aile mensen van 65 jaar en ouder en 
50% van die van 80 jaar en ouder gebruikt langdurig diuretica. De diureti-
ca worden in drie klassen ingedeeld: thiazides, lisdiuretica en kaliumspa-
rende diuretica. Hartfalen en hoge bloeddruk vormen de belangrijkste 
indicaties voordeze middelen. Hoewel hartfalen en hypertensie een hoge 
prevalentie hebben, krijgt men de indruk dat het grootschalige diuretica-
gebruik deels te wijten is aan het voortdurend herhalen van recepten 
zonder zorgvuldige evaluatievan de noodzaak daarvan. Hoewel diuretica 
betrekkelijk veilige geneesmiddelen zijn, zijn er toch potentieelgevaarlij-
ke bijwerkingen bekend. Onnodige therapieen dienen altijd te worden 
vermeden en diuretica vormen hierop geen uitzondering. Het doel van 
de belangrijkste in dit proefschrift beschreven onderzoekingen, is vast te 
stellen welk deel van de oudere patienten die onderhoudsmedicatie diu-
retica gebruiken, kan stoppen zonder nadelige invloed op hun gezond-
heid. Tevens werd door middel van literatuurstudies de huidige rol van 
diuretica bij de behandeling van hartfalen en hypertensie onderzocht. 
Aan de hand van zes recent gepubliceerde nationale richtlijnen voor de 
behandeling van chronisch hartfalen afkomstig uit Zweden, Canada, 
Verenigde Staten (2X) en Nederland (2X) wordt in llOofdstllk 2 de huidige 
rol van diuretica bij dit ziektebeeld beschreven. In elk van deze richtlij-
nen spelen diuretica een sleutelrol bij de therapie van hartfalen. Vijf van 
deze zes rapporten adviseren de combinatie van diuretica en ACE-rem-
mers als standaardtherapie. Aileen de richtlijn van het Nederlands Huis-
artsen Genootschap (NH G-Standaard) neemt een uitzonderingspositie in 
doormonotherapie met diuretica te adviseren als eerste stap in de behan-
delingvan lichtevormen van hartfalen. Aile richtlijnen adviseren bij een 
normale nierfunctie in eerste instantie thiazide diuretica te kiezen en die 
pas door furosemide te vervangen wanneer een sterker diuretisch effect 
gewenst is. Het verlagen van de diureticadosis bij klinisch stabiele pa-
tienten zonder tekenen van vochtretentie en het opnieuw verhogen van 
de dosis in geval van symptomen van vochtretentie, wordt in alle richtlij-
nen aangeraden. Voor patienten met hardnekklge vochtretentie ondan ks 
I26 Dillretic therapy: ClIrrent role mid effects of withdrawal 
aanzienlijke doses furosemide, wordt het combineren van furosemide 
met een thiazide of met spironolacton aanbevolen. Opva11end zijn de 
verschillen in de aanbevelingen over diuretische behandeling van pa-
tienten met diastolische linker ventrikel dysfunctie.ln sommige van de 
richtlijnen zijn diuretica eerste keus, terwijl andere ze als gecontra-indi-
ceerd beschouwen. De contrasterende aanbevelingen zijn in het geval 
van de rol van monotherapie met diuretica terug te voeren op verschillen 
in interpretatie van de resultaten van de grote trials, en in het geval van 
de rol van diuretica bij diastolische linkerventrikel dysfunctie op prema-
turiteit van deze diagnose als klinische entiteit. 
In l/Oofdstllk 3 wordt de hUidige rol van diuretica bij de behandeling van 
hypertensie besproken aan de hand van vijf recent gepubliceerde natio-
nale richtlijnen uit Nederland (2X), Canada, Engeland en de Verenigde 
Staten. De Canadese, de Amerikaanse, de Engelse en de Nederlandse NHG 
richtlijnen adviseren a11emaal diuretica of B-blockers als eerste keuze ge-
neesmiddelen bij hypertensie voor te schrijven. Nieuwere geneesmidde-
lengroepen voor de behandelingvan hypertensie, zoals ACE-remmers en 
calciumantagonisten worden hierbij niet als eerste keuze beschouwd, 
vanwege het ontbreken van gerandomiseerd onderzoek naar de effectivi-
teit van deze middelen op de morbiditeit en de mortaliteit. De Canadese 
en de Engelse richtlijnen spreken hun voorkeuruitvoorthiazidediuretica 
boven B-blokkers bij oudere patienten. Hypercholesterolaemie wordt niet 
beschouwd als reden om af te zien van het voorschrijven van thiazides, 
omdat de kleine stijgingvan de cholesterolconcentratie in het bloed die 
door deze middelen wordtveroorzaakt, als klinisch weinig relevantwordt 
beschouwd. Thiazide diuretica worden bij diabetes patienten niet als ab-
soluut gecontra-indiceerd beschouwd maar vanwege de ongunstige in-
vloed op het glucosemetabolisme wordt in de richtli jnen over het alge-
meen geadviseerd om diuretica bij diabeten niet als eerste keus voor te 
schrijven. Combinatiethera pie met thiazid es en kal iumsparende diuretica 
wordt niet aanbevolen als standaardbehandeling maar de Canadese en 
Engelse richtlijnen noemen deze combinatie weI als een mogeJijke eerste 
keus bij oudere patienten. In het licht van nieuwe onderzoeksresultaten 
Ii jkt de rol vankal iumsparende combinaties enigszins ondergewaardeerd. 
Met name voor de oudere hypertensiepatienten is in grote gerandomi-
seerde trials overduidelijk aangetoond dat kaliumsparende combinaties 
minstens zo effectief morbiditeit en mortaliteit verminderen als thiazides. 
In l/Oofdstllk 4 wordt een aantal methodologische aspecten besproken van 
onderzoekingen naar de effecten van het staken van langdurig gebruikte 
medicatie. Het inherente doel van dit soort onderzoekingen is het bepa-
len van de proportie patienten bij wie onnodig geneesmiddelgebruik kan 
worden venninderd. Een valkuil bij ditsoortonderzoekishettrekken van 
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conclusies over effectiviteit van het geneesmiddel, door het omkeren van 
effecten die optreden bij het staken. Er wordt gesteld dat het belang van 
de gerandomiseerde, gecontroleerde opzet bij dit soort studies even groot 
is als bij elk ander geneesmiddelonderzoek. In deze zogenoemde genees-
middel-stop-studies wordt de interventiegroep dan gevormd door pa-
tienten op placebomedicatie terwijl de controlegroep juist bestaat uit 
patienten op actieve medica tie. Door deze omkering ten opzichte van 
gebruikelijke geneesmiddelenonderzoeken is het beter te spreken van 
verum-gecontroleerd in plaats van placebo-gecontroleerd onderzoek. 
Blinderen van patienten en behandelaars is nodig wanneer het doel van 
het onderzoek de bestudering van de effecten van staken van het farma-
cologisch substraat behelst en niet wanneer de effecten van de stopproce-
dure als geheel onderwerp van studie zijn. Effectmaten die 'succes' in 
plaats van 'risico' als uitgangspunt hebben, kunnen nuttig zijn om het 
inzicht in de betekenis van de resu!taten van geneesmiddel-stop-studies 
te vergroten. Tenslotte wordt in dit hoofdstuk besproken dat het vermij-
den van statistische type I en type II fouten bij stop-studies even belang-
rijk is en dat op grand hiervan het aantal benodigde patienten in derge-
lijk onderzoek vergeleken met een effectiviteitsonderzoek groter zal zijn. 
De conclusie luidt dat geneesmiddel-stop-studies een belangrijk instru-
ment kunnen zijn om op rationele wijze (dreigende) overmedicatie te 
bestrijden, maar de opzet dient dan welmethodologisch juist te zijn. 
Hoo(dstllk 5 beschrijft een onderzoek naar de overeenstemming van een 
automatische oscillometrische bloeddrukmeter (Omron HEM403C) met 
een kwikmanometer (Hawksley random-zero meter). Hierbij werd gebruik 
gemaaktvan simultaan-metingen aan een arm. De luchtslangen van bei-
de meters waren met een T-stukje verbonden aan een en dezelfde arm-
manchet. Om de mate van overeenstemmingvan de twee meters vast te 
stellen werden bij 212 personen bloeddrukmetingen verricht. De systoli-
sche en diastolische bloeddrukwaarden waren met de Omron meter ge-
middeld respectievelijk I (sd 9, 950/0BJ 0,4 tot 2,2) en 4mmHg (sd 8, 950/0BI 
3,6 tot 5,1) hoger dan met de kwikmanometer. Naar de maatstaven van de 
British Hypertension Society bleek de Omron HEM403C (marginaal) vol-
doende nauwkeurig om aanbevolen te worden voor die klinische en re-
search toepassingen waarvoor automatische metingen de voorkeur genie-
ten. 
Een ongecontroleerde 'pilot' -shtdie (ilOo(dstllk 6) in de eigen praktijk van 
de auteur van dit proefschrift ging vooraf aan de uitvoering van een gro-
ter gerandomiseerd onderzoek (hoofdstuk 7). Dit werd gedaan om de 
haalbaarheid van de shtdieopzet te testen en om een schatting te maken 
van het aantal patienten dat met diuretica kon stoppen. De effecten van 
r28 Dillretic therapy: ClIrrellt role alld effects of withdrawal 
het stoppen van diuretica op de bloeddruk, een hartfalen-symptoom-
score, enkeloedeem, Iichaamsgewicht en subjectiefklachtenpatroon wer-
den gedurende zes maanden na het stoppen van het diureticum regelma-
tig gemeten. Ongeveer 20% van aile patienten van 65 jaar en ouder bleek 
onderhoudsmedicatie met diuretica te gebruiken. Van 38 opgespoorde 
patienten werden er 22 van het onderzoek uitgesloten, voornamelijk we-
gens manifest hartfalen of hoge bloeddruk. Een patient weigerde deelna-
me. Vervolgens werd onder intensieve medische controle bij 15 patienten 
de diuretische medicatie gestaakt. Na zes maanden waren zes patienten 
nogzonderdiuretica; in negen gevallen was de behandeling met diuretica 
hervatwegenshartfalen (n=I), hypertensie (n=3), bronchiaal astma (n=I), 
toegenomen enkeloedeem (n=2) en subjectieve klachten (n=2). Het stop-
pen met diuretica veroorzaakte een stijgingvan de systolische bloeddruk, 
de hartfaien-score, het Iichaamsgewicht en enkeloedeem. De conclusie 
iuidde dat onderhoudsbehandeling met diuretica in geselecteerde gevai-
ien bij oudere patienten in de huisartspraktijk kan worden gestaakt. 
In aansluiting op de 'pilot'- studie werd een gerandomiseerde, dubbel-
bHnde trial uitgevoerd naar de elfecten van het stoppen van onderhouds-
medicatie diuretica bij ouderen (hoofdstllk 7). Van 470, in acht hllisarts-
praktijken opgespoorde patienten die langdurig diuretica gebruikten, 
werden er 268 uitgesloten, wederom voornamelijk wegens hartfalen of 
hypertensie. De overige 202 patienten werden willekeurigtoegewezen aan 
hetzij de placebogroep (stop-groep), hetzij de groep die doorging met de 
onderhoudsmedicatie diuretica (controlegroep). Hetoptreden van klini-
scheverschijnselen waarvoor diuretische therapie nodig is-gedefinieerd 
vol gens tevoren vastgelegde criteria - was de belangrijkste uitkomstpara-
meter van het onderzoek. Gedurende een follow-up periode van zes 
maanden bleek hervattingvan diuretische therapie nodig bij 50 patienten 
in de stop-groep, terwijl in de controlegroep slechts bij 13 patienten addi-
tionele diuretica nodig waren (risicoverschil36%, 95%BI 20 tot 50%). De 
meestvoorkomende red en voor hervatten van de diuretica was het optre-
den van symptomen van hartfalen (25 van de 50 patienten). Het stoppen 
van de diuretica veroorzaakte een gemiddelde stijging van de systolisclle 
en diastolische bloeddruk van respectievelijk 13,5 (95%BI 9,2 tot 17,8) en 
4,6 (95%BI 1,9 tot 7,3) mmHg. De kans dat na het staken van diuretica een 
kllnische conditie ontstond die (additionele) therapie met diuretica 
noodzakelijkmaakte was hetmeest uitgesproken bij patienten die onder-
houdsmedicatie diuretica gebruikten voor de indica tie hartfalen (risico-
verschil57'Yo). Gunstige elIecten van het stoppen van diuretica waren een 
verlaging van de gemiddelde serumconcentraties van cholesterol, kreati-
nine en urinezllur. Ook natrium- en kaliumconcentraties gaven een ge-
middelde sti jgingte zien. De resultaten van dit onderzoek wijzen erop dat 
hetstoppen van onderhoudsmedicatie metdiuretica bij oudere patienten 
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in de meerderheid van de gevallen leidt tot het ontstaan van symptomen 
van hartfalen of hypertensieve bloeddrukwaarden. In een geselecteerde 
groep patienten, met hypertensie of niet·cardiaal oedeem als indicatie 
voor de dluretische therapie, kan het staken succesvol zijn, maar ook in 
deze groepen zi j n intensieve medische controles onontbeerli jk wegens de 
verhoogde kans op hartfalen. Dat risico is het grootst gedurende de eerste 
vier weken na het stoppen van de medicatie. 
In de algemene discussie (I/oofdstllk 8) wordt uitgewijd over een aantal 
onderwerpen die in dit proefschrift zijn beschreven, bijvoorbeeld het 
belang van nationale richtlijnen voor de behandeling van veel voorko· 
mende aandoeningen als hypertensie en hartfalen, en de discrepantie 
tussen het voorschrijfgedrag van artsen bij hypertensie en de aanbevelin-
gen in de hypertensie-rlchtlijnen. Tenslotte worden de potentiele impli-
caties van de in het proefschrift beschreven diuretica stop-studies voor de 
huisartspraktijk besproken. Enkele aanbevelingen omtrent de beslissing 
om onderhoudsmedicatie met diuretica al dan nlet voort te zetten en 
suggesties voor het controlebeleid na het staken van diuretica worden 
genoemd in de slotparagraaf. 
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